[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"BD Biosciences, Systems & Reagents\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":187},{"warningLetters":4,"total":186},[5,33,58,81,102,124,145,166],{"id":6,"raw":7,"subject":12,"body_html":15,"body_text":16,"firm_name":17,"letter_id":18,"created_at":19,"fei_number":20,"letter_url":21,"updated_at":22,"action_type":23,"case_status":24,"posted_date":25,"marcs_cms_no":26,"product_type":27,"closeout_date":28,"issuing_office":11,"recipient_name":29,"body_fetched_at":30,"delivery_method":31,"recipient_title":20,"reference_number":20,"action_taken_date":32,"medical_device_id":20,"response_letter_date":20},3560,[8,9,10,11,12,13,14,13],"\u003Ctime datetime=\"2021-02-02T14:20:00Z\">02\u002F02\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-01-06T05:00:00Z\">01\u002F06\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fentia-biosciences-inc-610493-01062021\">Entia Biosciences, Inc\u003C\u002Fa>","Division of Human and Animal Food Operations West VI","New Drug\u002FMisbranded","","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fentia-biosciences-inc-610493-04292021\">\u003Ctime datetime=\"2021-05-12T04:00:00Z\">05\u002F12\u002F2021\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Overnight Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Dietary Supplements\u003Cbr>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Timothy A. Timmins\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Entia Biosciences, Inc\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>13565 SW Tualatin Sherwood Road, Suite 800\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Sherwood\u003C\u002Fspan>, \u003Cspan>OR\u003C\u002Fspan> \u003Cspan>97140\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Human and Animal Food Operations West VI\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>January 6, 2021\u003C\u002Fp>\n\n\u003Cp>In reply, refer to CMS 610493\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Timmins:\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the US. Food and Drug Administration (FDA) reviewed your website at the Internet address www.totalnutraceutical.com in September 2020 and December 2020, and has determined that you take orders there for the products Lion's Mane -All Natural Supplement, Antrodia Mushroom Powder, Maitake Mushroom Powder, Reishi Mushroom Powder, Cordyceps Mushroom Powder, and Cordyceps - All Natural Mushroom Dietary Supplement. The claims on these websites establish that these products are drugs under section 201(g)(1)(8) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321 (g)(1 )(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA's home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that your products are intended for use as drugs include:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Lion's Mane - All Natural Supplement\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your product page at www.totalnutraceutical.com\u002Flions-mane-supplement contains the following claims:\u003C\u002Fp>\n\n\u003Cp>• \"Helps to lower cholesterol\"\u003Cbr>\n• \"Anti-inflammatory\"\u003Cbr>\n• \"It has been linked to having positive implications towards reducing cholesterol levels and inflammation\"\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Antrodia Mushroom Powder\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On your product page for Antrodia Mushroom Powder at www.totalnutraceutical.com\u002Fantrodia, you claim that your product has:\u003C\u002Fp>\n\n\u003Cp>• \"Anti-inflammatory properties,\" and\u003Cbr>\n• \" ... [t]he Antrodia mushroom has long been used as a potent anti-inflammatory for a variety of conditions including liver disease, hypertension ... It is also used to help increase the body's defenses and prevent illness\"\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Maitake Mushroom Powder\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your product page for Maitake Mushroom Powder at www.totalnutraceutical.com\u002Fmaitake states that the product:\u003C\u002Fp>\n\n\u003Cp>• \"Promotes balanced blood sugar,\" and that the mushroom has been\u003Cbr>\n• \"Found to also have cancer fighting properties\"\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Reishi Mushroom Powder\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On your product page for Reishi Mushroom at www.totalnutraceutical.com\u002Fmushroomsreishi, you state the following:\u003C\u002Fp>\n\n\u003Cp>\"There are many reported health benefits of the Reishi mushroom. Some of these include:\u003C\u002Fp>\n\n\u003Cp>• Relief of viral infections ...\u003Cbr>\n• Prevention of heart disease\u003Cbr>\n• Reduce high blood pressure\u003Cbr>\n• Lower high cholesterol\u003Cbr>\n• Prevention of prostate cancer\u003Cbr>\n• Strong anti-inflammatory properties\"\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Cordyceps Mushroom Powder\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On your product page for Cordyceps Mushroom at www.totalnutraceutical.com\u002Fmushrooms-cordyceps, you state the following:\u003C\u002Fp>\n\n\u003Cp>\"There are many reported health benefits of the cordyceps mushroom. Some of these include:\u003C\u002Fp>\n\n\u003Cp>• Cholesterol reduction\u003Cbr>\n• Promotes balanced blood sugar ...\u003Cbr>\n• Faster recovery from bronchitis and respiratory diseases ...\u003Cbr>\n• Anti-tumor ...\u003Cbr>\n• ... enhanced recovery from chemotherapy\"\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Cordyceps - All Natural Mushroom Dietary Supplement\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On your product page at www.totalnutraceutical.com\u002Fcordyceps-supplement, you claim:\u003C\u002Fp>\n\n\u003Cp>• \"Promotes balanced blood sugar\"\u003Cbr>\n• \" ... Cordyceps has long been used to treat a variety of health conditions. Its properties range from promoting lower cholesterol to balancing blood sugar levels.\"\u003C\u002Fp>\n\n\u003Cp>Your Lion's Mane -All Natural Supplement, Antrodia Mushroom Powder, Maitake Mushroom Powder, Reishi Mushroom Powder, Cordyceps Mushroom Powder, and Cordyceps -All Natural Mushroom Dietary Supplement products are not generally recognized as safe and effective for the above-referenced uses and, therefore, the products are \"new drugs\" under section 201 (p) of the Act [21 U.S.C. § 321 (p)]. New drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301 (d) and 505(a) of the Act [21 U.S.C. §§ 331 (d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). \"Adequate directions for use\" means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003Cbr>\n\u003Cbr>\nYour products Lion's Mane -All Natural Supplement, Antrodia Mushroom Powder, Maitake Mushroom Powder, Reishi Mushroom Powder, Cordyceps Mushroom Powder, and Cordyceps - All Natural Mushroom Dietary Supplement are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use these products safely for their intended purposes. Accordingly, your Lion's Mane -All Natural Supplement, Antrodia Mushroom Powder, Maitake Mushroom Powder, Reishi Mushroom Powder, Cordyceps Mushroom Powder, and Cordyceps - All Natural Mushroom Dietary Supplement products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301 (a) of the Act [21 U.S.C. § 331 (a)].\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of violations that exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>You should take prompt action to correct or implement corrections to the violations cited in this letter. Failure to promptly correct these violations may result in legal action without further notice, including, without limitation, seizure and\u002For injunction.\u003C\u002Fp>\n\n\u003Cp>Within fifteen ( 15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to correct violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction.\u003C\u002Fp>\n\n\u003Cp>Your written reply should be sent to the Food and Drug Administration, Attention: Mark Babbitt, Compliance Officer, 22215 26th Avenue SE, Suite 210, Bothell, Washington 98021-4421. If you have any questions, please contact Mark Babbitt at \u003Cspan>509-353-2136\u003Ca>\u003C\u002Fa>\u003C\u002Fspan> ext. 107.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nMiriam R. Burbach\u003Cbr>\nDistrict Director\u003Cbr>\nProgram Division Director\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nOvernight Mail\n\nProduct:\n\nDietary Supplements\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nTimothy A. Timmins\n\nRecipient Title\n\nPresident\n\nEntia Biosciences, Inc\n\n13565 SW Tualatin Sherwood Road, Suite 800\n\nSherwood, OR 97140\n\nUnited States\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations West VI\n\nUnited States\n\nJanuary 6, 2021\n\nIn reply, refer to CMS 610493\n\nWARNING LETTER\n\nDear Mr. Timmins:\n\nThis is to advise you that the US. Food and Drug Administration (FDA) reviewed your website at the Internet address www.totalnutraceutical.com in September 2020 and December 2020, and has determined that you take orders there for the products Lion's Mane -All Natural Supplement, Antrodia Mushroom Powder, Maitake Mushroom Powder, Reishi Mushroom Powder, Cordyceps Mushroom Powder, and Cordyceps - All Natural Mushroom Dietary Supplement. The claims on these websites establish that these products are drugs under section 201(g)(1)(8) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321 (g)(1 )(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA's home page at www.fda.gov.\n\nExamples of some of the website claims that provide evidence that your products are intended for use as drugs include:\n\nLion's Mane - All Natural Supplement\n\nYour product page at www.totalnutraceutical.com\u002Flions-mane-supplement contains the following claims:\n\n• \"Helps to lower cholesterol\"\n\n• \"Anti-inflammatory\"\n\n• \"It has been linked to having positive implications towards reducing cholesterol levels and inflammation\"\n\nAntrodia Mushroom Powder\n\nOn your product page for Antrodia Mushroom Powder at www.totalnutraceutical.com\u002Fantrodia, you claim that your product has:\n\n• \"Anti-inflammatory properties,\" and\n\n• \" ... [t]he Antrodia mushroom has long been used as a potent anti-inflammatory for a variety of conditions including liver disease, hypertension ... It is also used to help increase the body's defenses and prevent illness\"\n\nMaitake Mushroom Powder\n\nYour product page for Maitake Mushroom Powder at www.totalnutraceutical.com\u002Fmaitake states that the product:\n\n• \"Promotes balanced blood sugar,\" and that the mushroom has been\n\n• \"Found to also have cancer fighting properties\"\n\nReishi Mushroom Powder\n\nOn your product page for Reishi Mushroom at www.totalnutraceutical.com\u002Fmushroomsreishi, you state the following:\n\n\"There are many reported health benefits of the Reishi mushroom. Some of these include:\n\n• Relief of viral infections ...\n\n• Prevention of heart disease\n\n• Reduce high blood pressure\n\n• Lower high cholesterol\n\n• Prevention of prostate cancer\n\n• Strong anti-inflammatory properties\"\n\nCordyceps Mushroom Powder\n\nOn your product page for Cordyceps Mushroom at www.totalnutraceutical.com\u002Fmushrooms-cordyceps, you state the following:\n\n\"There are many reported health benefits of the cordyceps mushroom. Some of these include:\n\n• Cholesterol reduction\n\n• Promotes balanced blood sugar ...\n\n• Faster recovery from bronchitis and respiratory diseases ...\n\n• Anti-tumor ...\n\n• ... enhanced recovery from chemotherapy\"\n\nCordyceps - All Natural Mushroom Dietary Supplement\n\nOn your product page at www.totalnutraceutical.com\u002Fcordyceps-supplement, you claim:\n\n• \"Promotes balanced blood sugar\"\n\n• \" ... Cordyceps has long been used to treat a variety of health conditions. Its properties range from promoting lower cholesterol to balancing blood sugar levels.\"\n\nYour Lion's Mane -All Natural Supplement, Antrodia Mushroom Powder, Maitake Mushroom Powder, Reishi Mushroom Powder, Cordyceps Mushroom Powder, and Cordyceps -All Natural Mushroom Dietary Supplement products are not generally recognized as safe and effective for the above-referenced uses and, therefore, the products are \"new drugs\" under section 201 (p) of the Act [21 U.S.C. § 321 (p)]. New drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301 (d) and 505(a) of the Act [21 U.S.C. §§ 331 (d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). \"Adequate directions for use\" means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour products Lion's Mane -All Natural Supplement, Antrodia Mushroom Powder, Maitake Mushroom Powder, Reishi Mushroom Powder, Cordyceps Mushroom Powder, and Cordyceps - All Natural Mushroom Dietary Supplement are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use these products safely for their intended purposes. Accordingly, your Lion's Mane -All Natural Supplement, Antrodia Mushroom Powder, Maitake Mushroom Powder, Reishi Mushroom Powder, Cordyceps Mushroom Powder, and Cordyceps - All Natural Mushroom Dietary Supplement products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301 (a) of the Act [21 U.S.C. § 331 (a)].\n\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations that exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nYou should take prompt action to correct or implement corrections to the violations cited in this letter. Failure to promptly correct these violations may result in legal action without further notice, including, without limitation, seizure and\u002For injunction.\n\nWithin fifteen ( 15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to correct violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction.\n\nYour written reply should be sent to the Food and Drug Administration, Attention: Mark Babbitt, Compliance Officer, 22215 26th Avenue SE, Suite 210, Bothell, Washington 98021-4421. If you have any questions, please contact Mark Babbitt at 509-353-2136 ext. 107.\n\nSincerely,\n\n\u002FS\u002F\n\nMiriam R. Burbach\n\nDistrict Director\n\nProgram Division Director","Entia Biosciences, Inc","entia-biosciences-inc-610493-01062021","2026-08-18T06:42:29.460824+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fentia-biosciences-inc-610493-01062021","2026-10-26T08:08:35.712624+00:00","Warning Letter","Closed Out","2021-02-02","610493","Dietary SupplementsFood & Beverages","2021-05-12","Timothy A. Timmins","2026-08-20T03:25:06.576+00:00","Overnight Mail","2021-01-06",{"id":34,"raw":35,"subject":41,"body_html":42,"body_text":43,"firm_name":44,"letter_id":45,"created_at":46,"fei_number":20,"letter_url":47,"updated_at":48,"action_type":23,"case_status":49,"posted_date":50,"marcs_cms_no":51,"product_type":52,"closeout_date":20,"issuing_office":39,"recipient_name":53,"body_fetched_at":54,"delivery_method":55,"recipient_title":20,"reference_number":56,"action_taken_date":57,"medical_device_id":20,"response_letter_date":20},1073,[36,37,38,39,40,13,13,13],"\u003Ctime datetime=\"2025-02-04T05:00:00Z\">02\u002F04\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-01-17T05:00:00Z\">01\u002F17\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbiostem-life-sciences-673788-01172025\">BioStem Life Sciences\u003C\u002Fa>","Center for Biologics Evaluation and Research (CBER)","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues &amp; Cellular Products (HCT\u002FPs)","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues & Cellular Products (HCT\u002FPs)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>CBER 25-673788\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jason V. Matuszewski\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>BioStem Life Sciences\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2836 Center Port Circle\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Pompano Beach\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33064\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:quality@biostemtech.com\"> quality@biostemtech.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research (CBER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cbr>January 17, 2025&nbsp;\u003C\u002Fp>\u003Cp>CBER 25-673788\u003C\u002Fp>\u003Cp>Dear Mr. Matuszewski:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your facility, located at the above address, between September 11, 2023, and September 15, 2023. During the inspection, FDA documented that your company manufactures cellular products derived from human umbilical cord, including those labeled as Product 401 (OROPRO®), Product 403 (PROVISCUS®), and Product 404 (NEOFYL®) as well as an amniotic membrane combined with amniotic fluid product labeled as RHEO® (collectively, “your products”).&nbsp;\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of current good manufacturing practice (CGMP) requirements, including violations of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. § 351(a)(2)(B), and 21 CFR parts 210 and 211. Because your methods, facilities, or controls for manufacturing, processing, packing, or holding drugs do not conform to CGMP, your products are adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. § 351(a)(2)(B). Your adulteration of your products while held for sale after shipment in interstate commerce, or the causing thereof, is a prohibited act under section 301(k) of the FD&amp;C Act, 21 U.S.C. § 331(k).&nbsp;\u003C\u002Fp>\u003Cp>Based on information and records reviewed by FDA, your products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body. For example,\u003C\u002Fp>\u003Cul>\u003Cli>\u003Cp>NEOFYL®\u003Cbr>o &nbsp;“Instead of treating pain and injury with surgery and drugs, regenerative medicine supplements your body’s own healing system with natural growth factors, cytokines, collagens, and other proteins. This array of components helps cushion and support damaged tissue and joints while providing structure and ideal microenvironment conditions for rebuilding.”&nbsp;\u003C\u002Fp>\u003Cp>o &nbsp;“The umbilical cord contains a collagenous matrix that is rich in hyaluronic acid, growth factors, and other cytokines. These elements are reported to have anti-inflammatory, anti-bacterial, and anti-scarring properties, making umbilical cord tissue an attractive biomaterial for use in an outpatient clinic or surgical procedures.”\u003C\u002Fp>\u003C\u002Fli>\u003Cli>OROPRO®\u003Cbr>o &nbsp;“Regenerative medicine harnesses your body’s own ability to heal and boosts it in a very powerful and effective way.”\u003Cbr>o &nbsp;“Umbilical cord and Wharton’s jelly allografts demonstrate anti-inflammatory, anti-bacterial and anti-fibrotic properties that support repair of damaged tissue.”\u003C\u002Fli>\u003Cli>PROVISCUS®\u003Cbr>o &nbsp;“Instead of treating pain and injury with surgery and drugs, regenerative medicine supplements your body’s own healing system with natural growth factors, cytokines, collagens, and other proteins.”\u003C\u002Fli>\u003Cli>RHEO®\u003Cbr>o &nbsp;“RHEO® is a human perinatal tissue allograft derived from the extracellular matrix of the amniotic membrane. It is aseptically processed to preserve the endogenous cytokines, growth factors and scaffolding proteins present within the amniotic tissue matrix… By supplementing damaged tissue with these factors, you can stimulate the same scaffold creation naturally found in the body and allow the tissue to ‘self-heal’.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Therefore, your products are drugs as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(i).\u003C\u002Fp>\u003Cp>Your cellular products derived from human umbilical cord labeled as Product 401 (OROPRO®), Product 403 (PROVISCUS®), and Product 404 (NEOFYL®) as well as an amniotic membrane combined with amniotic fluid product labeled as RHEO® are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a) are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271. Unless an exception in 21 CFR 1271.15 applies, such products are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act and are subject to additional regulation, including applicable premarket review. Based on a review of relevant materials, Biostem Life Sciences does not qualify for any exception in 21 CFR 1271.15, and your products fail to meet all criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\u003Cp>For example, your cellular products derived from human umbilical cord labeled as Product 401 (OROPRO®), Product 403 (PROVISCUS®), and Product 404 (NEOFYL®) as well as an amniotic membrane combined with amniotic fluid product labeled as RHEO® fail to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because your processing alters the original relevant characteristics of the umbilical cord (of products OROPRO®, PROVISCUS® and NEOFYL®) and amniotic membrane (of RHEO®) related to their utility for reconstruction, repair, or replacement. The processing of the umbilical cord from the form of a conduit into an injectable form drastically alters the physical state of the HCT\u002FP. The umbilical cord is more than minimally manipulated because such processing alters the original relevant characteristics of the HCT\u002FP relating to its utility to serve as a conduit by effectively altering or eliminating its physical integrity and tubular form. The processing of the amniotic membrane from the form of a sheet into an injectable form drastically alters the physical state of the HCT\u002FP. The amniotic membrane is more than minimally manipulated because such processing alters the original relevant characteristics of the HCT\u002FP relating to its utility to serve as a barrier by effectively altering or eliminating its physical integrity, tensile strength, and elasticity.\u003C\u002Fp>\u003Cp>In addition, your products fail to meet the criterion that the HCT\u002FPs be “intended for homologous use only,” which means that the “labeling, advertising, or other indications of the manufacturer’s objective intent” demonstrate that the HCT\u002FP is intended to perform “the same basic function or functions in the recipient as in the donor.” 21 CFR 1271.3(c) and 1271.10(a)(2). Your products are not intended solely to perform the same basic function or functions of the HCT\u002FP in the recipient as in the donor (e.g., serving as a conduit for umbilical cord or serving as a barrier for amniotic membrane). Rather, your products are intended for use in treating damaged tissues and joints, which are not basic functions of the umbilical cord and amniotic membrane in the donor.\u003C\u002Fp>\u003Cp>Therefore, these HCT\u002FPs are not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> See 21 CFR 1271.20. In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, your products are regulated as drugs as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as stated above.\u003C\u002Fp>\u003Cp>Subject to certain exceptions not applicable here, to lawfully introduce or deliver for introduction into interstate commerce a drug that is a biological product, a valid biologics license application (BLA) must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. Your products are not the subject of an approved BLA.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>CGMP Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA’s inspection of your facility documented evidence of significant CGMP violations. At the conclusion of the inspection, FDA investigators issued a Form FDA-483, List of Inspectional Observations (Form FDA-483). FDA identified additional significant violations upon further review of the evidence collected during the inspection, as set forth below.\u003C\u002Fp>\u003Cp>The CGMP violations applicable to your products include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas to prevent contamination [21 CFR 211.42(c)(10)(iv)].\u003C\u002Fstrong> For example,\u003C\u002Fp>\u003Cp>a. Your firm has not performed routine (i.e., during every production batch) non-viable particulate monitoring and surface sampling of the critical area (i.e., \u003Cstrong>(b)(4)\u003C\u002Fstrong> where your products are exposed to the environment). The environmental monitoring frequencies described in SOP QCD-034 titled, “Environmental Controls and Monitoring Procedure” (Effective date: December 12, 2022) are not sufficient to detect potential environmental contamination risks and demonstrate control inside the critical manufacturing area during manufacturing.\u003C\u002Fp>\u003Cp>b. Your firm does not require microbiological monitoring of operators’ arm coverings used in the critical aseptic processing area for manually processing your products.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Your firm failed to establish an adequate system for cleaning and disinfecting the room and equipment to produce aseptic conditions [21 CFR 211.42(c)(10)(v)].\u003C\u002Fstrong> For example, your firm has failed to validate your procedure for cleaning and disinfecting the ISO 5 \u003Cstrong>(b)(4)\u003C\u002Fstrong> and supporting ISO 7 cleanroom where your products are manufactured. Validation of a cleaning process is needed to verify suitable cleaning and disinfecting agents are used to remove potential microbial contaminants from the critical manufacturing areas where your products are exposed during manufacturing.\u003C\u002Fp>\u003Cp>\u003Cstrong>3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)].\u003C\u002Fstrong> For example, your firm has not adequately validated your manufacturing processes for your products with respect to identity, strength, quality, and purity. Your testing is limited to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. These are not sufficient measures of identity, strength, quality, and purity.\u003C\u002Fp>\u003Cp>Process validation studies determine whether an initial state of control has been established while routine monitoring of process performance and product attributes determines whether control is maintained. Establishment of appropriate attributes relating to identity, strength, quality, and purity of drug products is essential for assuring product quality over the product lifecycle.\u003C\u002Fp>\u003Cp>\u003Cstrong>4. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications designed to assure that drug products conform to appropriate standards of identity, strength, quality, and purity [21 CFR 211.160(b)].\u003C\u002Fstrong> The review of batch records and procedure QAD-040 titled “Product Release” (Effective date: September 5, 2023) indicate final product testing is limited to sterility testing and endotoxin testing as measurements of product attributes and such testing does not demonstrate, for example, the identity and\u002For strength of your products.\u003C\u002Fp>\u003Cp>\u003Cstrong>5. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates [21 CFR 211.166(a)].\u003C\u002Fstrong> For example, your firm assigned expiration dates between \u003Cstrong>(b)(4)\u003C\u002Fstrong> months to your products without adequate supporting data that conform to appropriate standards of identity, strength, quality, and purity. For example, your expiration summary reports for RHEO® is limited to \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterility testing only while Product 401 (OROPRO®) is limited to \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterility and endotoxin testing. Product 403 (PROVISCUS®) and Product 404 (NEOFYL®) are limited to Hyaluronic Acid concentration only. Appropriate standards of identity, strength, quality, and purity during intervals through the expiry period are needed to ensure product attributes remain for the shelf life of the product.\u003C\u002Fp>\u003Cp>\u003Cstrong>Responses to the Form FDA-483\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We acknowledge receipt of your correspondences dated September 29, 2023; October 13, 2023; October 27, 2023; November 10, 2023; November 28, 2023; December 8; 2023; December 22, 2023; January 5, 2024; January 9, 2024; February 29, 2024 and September 3, 2024 that provide a response to FDA’s inspectional observations and describe certain corrective actions. We have reviewed your responses and represented corrective actions and have found that they are inadequate. While you assert that your products were manufactured under section 361 of the PHS Act (and thus are not subject to cGMP regulations), the available evidence shows that your products do not meet the relevant criteria to be regulated solely under section 361 of the PHS Act. We acknowledge your commitment to submit a Pre-Request for Designation to FDA by February 29, 2024; however, this process remains incomplete, for you have not responded to the agency’s request for additional information. According to your correspondence, RHEO®, OROPRO®, and 403\u002F404 products have been removed from the market and shall no longer be manufactured by your firm. Your responses do not describe actions you have taken or plan to take to address the impact of the above-described CGMP deficiencies on your distributed products that carry a \u003Cstrong>(b)(4)\u003C\u002Fstrong>-month shelf life and remain within expiry.\u003C\u002Fp>\u003Cp>\u003Cstrong>Additional Concern\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In addition to the violations described above, we offer the following comment:\u003C\u002Fp>\u003Cul>\u003Cli>We note that the Instructions for Use for each of your products state, “This allograft is processed aseptically, but is not sterile.” If your products are not sterile, FDA has serious safety concerns regarding their use on patients via injection.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> FDA expects injectable products to be sterile, consistent with basic quality standards and to ensure patient safety.\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Be advised that, under 21 CFR 211.113(b), appropriate written procedures, designed to prevent microbiological contamination of drug products purporting to be sterile, shall be established and followed, including validation of aseptic and sterilization processes. Please address this issue in your response.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Neither this letter nor the observations noted on the Form FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with all applicable requirements in the FD&amp;C Act, PHS Act, and all applicable regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice including, without limitation, seizure and\u002For injunction.\u003C\u002Fp>\u003Cp>Please submit your response in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your products are in violation of the FD&amp;C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Send your electronic response to CBERDCMRecommendations@fda.hhs.gov. If you have questions regarding this letter, contact the Division of Case Management, CBER at (240) 402-9156.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Melissa J. Mendoza\u003Cbr>Director\u003Cbr>Office of Compliance and Biologics Quality\u003Cbr>Center for Biologics Evaluation and Research\u003C\u002Fp>\u003Cp>________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Because your products fail to meet at least one criterion in 21 CFR 1271.10(a), this letter does not address whether this product meets other criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> The preparation instructions in the IFUs for your products state, “Apply the allograft using an 18g or larger needle. If applied topically, utilize aseptic technique and caution.” While intravenous or intrathecal application are contraindicated, injection is not contraindicated.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> See, e.g., USP&lt;1&gt; (“Parenteral articles are prepared scrupulously by methods designed to ensure that they meet Pharmacopeial requirements for sterility, pyrogens, particulate matter, and other contaminants, and, where appropriate, contain inhibitors of the growth of microorganisms.”).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nCBER 25-673788\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nJason V. Matuszewski\n\nRecipient Title\n\nChief Executive Officer\n\nBioStem Life Sciences\n\n2836 Center Port Circle\n\nPompano Beach, FL 33064\n\nUnited States\n\nquality@biostemtech.com\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research (CBER)\n\nUnited States\n\nWARNING LETTER\n\nJanuary 17, 2025\nCBER 25-673788\nDear Mr. Matuszewski:\nThe United States Food and Drug Administration (FDA) inspected your facility, located at the above address, between September 11, 2023, and September 15, 2023. During the inspection, FDA documented that your company manufactures cellular products derived from human umbilical cord, including those labeled as Product 401 (OROPRO®), Product 403 (PROVISCUS®), and Product 404 (NEOFYL®) as well as an amniotic membrane combined with amniotic fluid product labeled as RHEO® (collectively, “your products”).\nThis warning letter summarizes significant violations of current good manufacturing practice (CGMP) requirements, including violations of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 351(a)(2)(B), and 21 CFR parts 210 and 211. Because your methods, facilities, or controls for manufacturing, processing, packing, or holding drugs do not conform to CGMP, your products are adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. § 351(a)(2)(B). Your adulteration of your products while held for sale after shipment in interstate commerce, or the causing thereof, is a prohibited act under section 301(k) of the FD&C Act, 21 U.S.C. § 331(k).\nBased on information and records reviewed by FDA, your products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body. For example,\nNEOFYL®\no “Instead of treating pain and injury with surgery and drugs, regenerative medicine supplements your body’s own healing system with natural growth factors, cytokines, collagens, and other proteins. This array of components helps cushion and support damaged tissue and joints while providing structure and ideal microenvironment conditions for rebuilding.”\no “The umbilical cord contains a collagenous matrix that is rich in hyaluronic acid, growth factors, and other cytokines. These elements are reported to have anti-inflammatory, anti-bacterial, and anti-scarring properties, making umbilical cord tissue an attractive biomaterial for use in an outpatient clinic or surgical procedures.”\n\nOROPRO®\no “Regenerative medicine harnesses your body’s own ability to heal and boosts it in a very powerful and effective way.”\no “Umbilical cord and Wharton’s jelly allografts demonstrate anti-inflammatory, anti-bacterial and anti-fibrotic properties that support repair of damaged tissue.”\nPROVISCUS®\no “Instead of treating pain and injury with surgery and drugs, regenerative medicine supplements your body’s own healing system with natural growth factors, cytokines, collagens, and other proteins.”\nRHEO®\no “RHEO® is a human perinatal tissue allograft derived from the extracellular matrix of the amniotic membrane. It is aseptically processed to preserve the endogenous cytokines, growth factors and scaffolding proteins present within the amniotic tissue matrix… By supplementing damaged tissue with these factors, you can stimulate the same scaffold creation naturally found in the body and allow the tissue to ‘self-heal’.”\nTherefore, your products are drugs as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(i).\nYour cellular products derived from human umbilical cord labeled as Product 401 (OROPRO®), Product 403 (PROVISCUS®), and Product 404 (NEOFYL®) as well as an amniotic membrane combined with amniotic fluid product labeled as RHEO® are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a) are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271. Unless an exception in 21 CFR 1271.15 applies, such products are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act and are subject to additional regulation, including applicable premarket review. Based on a review of relevant materials, Biostem Life Sciences does not qualify for any exception in 21 CFR 1271.15, and your products fail to meet all criteria in 21 CFR 1271.10(a).\nFor example, your cellular products derived from human umbilical cord labeled as Product 401 (OROPRO®), Product 403 (PROVISCUS®), and Product 404 (NEOFYL®) as well as an amniotic membrane combined with amniotic fluid product labeled as RHEO® fail to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because your processing alters the original relevant characteristics of the umbilical cord (of products OROPRO®, PROVISCUS® and NEOFYL®) and amniotic membrane (of RHEO®) related to their utility for reconstruction, repair, or replacement. The processing of the umbilical cord from the form of a conduit into an injectable form drastically alters the physical state of the HCT\u002FP. The umbilical cord is more than minimally manipulated because such processing alters the original relevant characteristics of the HCT\u002FP relating to its utility to serve as a conduit by effectively altering or eliminating its physical integrity and tubular form. The processing of the amniotic membrane from the form of a sheet into an injectable form drastically alters the physical state of the HCT\u002FP. The amniotic membrane is more than minimally manipulated because such processing alters the original relevant characteristics of the HCT\u002FP relating to its utility to serve as a barrier by effectively altering or eliminating its physical integrity, tensile strength, and elasticity.\nIn addition, your products fail to meet the criterion that the HCT\u002FPs be “intended for homologous use only,” which means that the “labeling, advertising, or other indications of the manufacturer’s objective intent” demonstrate that the HCT\u002FP is intended to perform “the same basic function or functions in the recipient as in the donor.” 21 CFR 1271.3(c) and 1271.10(a)(2). Your products are not intended solely to perform the same basic function or functions of the HCT\u002FP in the recipient as in the donor (e.g., serving as a conduit for umbilical cord or serving as a barrier for amniotic membrane). Rather, your products are intended for use in treating damaged tissues and joints, which are not basic functions of the umbilical cord and amniotic membrane in the donor.\nTherefore, these HCT\u002FPs are not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.1 See 21 CFR 1271.20. In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, your products are regulated as drugs as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as stated above.\nSubject to certain exceptions not applicable here, to lawfully introduce or deliver for introduction into interstate commerce a drug that is a biological product, a valid biologics license application (BLA) must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. Your products are not the subject of an approved BLA.\nCGMP Violations\nFDA’s inspection of your facility documented evidence of significant CGMP violations. At the conclusion of the inspection, FDA investigators issued a Form FDA-483, List of Inspectional Observations (Form FDA-483). FDA identified additional significant violations upon further review of the evidence collected during the inspection, as set forth below.\nThe CGMP violations applicable to your products include, but are not limited to, the following:\n1. Your firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas to prevent contamination [21 CFR 211.42(c)(10)(iv)]. For example,\na. Your firm has not performed routine (i.e., during every production batch) non-viable particulate monitoring and surface sampling of the critical area (i.e., (b)(4) where your products are exposed to the environment). The environmental monitoring frequencies described in SOP QCD-034 titled, “Environmental Controls and Monitoring Procedure” (Effective date: December 12, 2022) are not sufficient to detect potential environmental contamination risks and demonstrate control inside the critical manufacturing area during manufacturing.\nb. Your firm does not require microbiological monitoring of operators’ arm coverings used in the critical aseptic processing area for manually processing your products.\n2. Your firm failed to establish an adequate system for cleaning and disinfecting the room and equipment to produce aseptic conditions [21 CFR 211.42(c)(10)(v)]. For example, your firm has failed to validate your procedure for cleaning and disinfecting the ISO 5 (b)(4) and supporting ISO 7 cleanroom where your products are manufactured. Validation of a cleaning process is needed to verify suitable cleaning and disinfecting agents are used to remove potential microbial contaminants from the critical manufacturing areas where your products are exposed during manufacturing.\n3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)]. For example, your firm has not adequately validated your manufacturing processes for your products with respect to identity, strength, quality, and purity. Your testing is limited to (b)(4). These are not sufficient measures of identity, strength, quality, and purity.\nProcess validation studies determine whether an initial state of control has been established while routine monitoring of process performance and product attributes determines whether control is maintained. Establishment of appropriate attributes relating to identity, strength, quality, and purity of drug products is essential for assuring product quality over the product lifecycle.\n4. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications designed to assure that drug products conform to appropriate standards of identity, strength, quality, and purity [21 CFR 211.160(b)]. The review of batch records and procedure QAD-040 titled “Product Release” (Effective date: September 5, 2023) indicate final product testing is limited to sterility testing and endotoxin testing as measurements of product attributes and such testing does not demonstrate, for example, the identity and\u002For strength of your products.\n5. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates [21 CFR 211.166(a)]. For example, your firm assigned expiration dates between (b)(4) months to your products without adequate supporting data that conform to appropriate standards of identity, strength, quality, and purity. For example, your expiration summary reports for RHEO® is limited to (b)(4) sterility testing only while Product 401 (OROPRO®) is limited to (b)(4) sterility and endotoxin testing. Product 403 (PROVISCUS®) and Product 404 (NEOFYL®) are limited to Hyaluronic Acid concentration only. Appropriate standards of identity, strength, quality, and purity during intervals through the expiry period are needed to ensure product attributes remain for the shelf life of the product.\nResponses to the Form FDA-483\nWe acknowledge receipt of your correspondences dated September 29, 2023; October 13, 2023; October 27, 2023; November 10, 2023; November 28, 2023; December 8; 2023; December 22, 2023; January 5, 2024; January 9, 2024; February 29, 2024 and September 3, 2024 that provide a response to FDA’s inspectional observations and describe certain corrective actions. We have reviewed your responses and represented corrective actions and have found that they are inadequate. While you assert that your products were manufactured under section 361 of the PHS Act (and thus are not subject to cGMP regulations), the available evidence shows that your products do not meet the relevant criteria to be regulated solely under section 361 of the PHS Act. We acknowledge your commitment to submit a Pre-Request for Designation to FDA by February 29, 2024; however, this process remains incomplete, for you have not responded to the agency’s request for additional information. According to your correspondence, RHEO®, OROPRO®, and 403\u002F404 products have been removed from the market and shall no longer be manufactured by your firm. Your responses do not describe actions you have taken or plan to take to address the impact of the above-described CGMP deficiencies on your distributed products that carry a (b)(4)-month shelf life and remain within expiry.\nAdditional Concern\nIn addition to the violations described above, we offer the following comment:\nWe note that the Instructions for Use for each of your products state, “This allograft is processed aseptically, but is not sterile.” If your products are not sterile, FDA has serious safety concerns regarding their use on patients via injection.2 FDA expects injectable products to be sterile, consistent with basic quality standards and to ensure patient safety.3 Be advised that, under 21 CFR 211.113(b), appropriate written procedures, designed to prevent microbiological contamination of drug products purporting to be sterile, shall be established and followed, including validation of aseptic and sterilization processes. Please address this issue in your response.\nConclusion\nNeither this letter nor the observations noted on the Form FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with all applicable requirements in the FD&C Act, PHS Act, and all applicable regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice including, without limitation, seizure and\u002For injunction.\nPlease submit your response in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your products are in violation of the FD&C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\nSend your electronic response to CBERDCMRecommendations@fda.hhs.gov. If you have questions regarding this letter, contact the Division of Case Management, CBER at (240) 402-9156.\nSincerely,\n\u002FS\u002F\nMelissa J. Mendoza\nDirector\nOffice of Compliance and Biologics Quality\nCenter for Biologics Evaluation and Research\n________________________\n1 Because your products fail to meet at least one criterion in 21 CFR 1271.10(a), this letter does not address whether this product meets other criteria in 21 CFR 1271.10(a).\n2 The preparation instructions in the IFUs for your products state, “Apply the allograft using an 18g or larger needle. If applied topically, utilize aseptic technique and caution.” While intravenous or intrathecal application are contraindicated, injection is not contraindicated.\n3 See, e.g., USP\u003C1> (“Parenteral articles are prepared scrupulously by methods designed to ensure that they meet Pharmacopeial requirements for sterility, pyrogens, particulate matter, and other contaminants, and, where appropriate, contain inhibitors of the growth of microorganisms.”).","BioStem Life Sciences","biostem-life-sciences-673788-01172025","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbiostem-life-sciences-673788-01172025","2026-10-26T08:08:05.524573+00:00","Issued","2025-02-04","673788","Biologics","Jason V. Matuszewski","2026-08-19T17:02:42.585+00:00","VIA UPS and Electronic Mail","CBER 25-673788","2025-01-17",{"id":59,"raw":60,"subject":65,"body_html":66,"body_text":67,"firm_name":68,"letter_id":69,"created_at":70,"fei_number":20,"letter_url":71,"updated_at":72,"action_type":23,"case_status":49,"posted_date":73,"marcs_cms_no":74,"product_type":75,"closeout_date":20,"issuing_office":64,"recipient_name":76,"body_fetched_at":77,"delivery_method":78,"recipient_title":20,"reference_number":79,"action_taken_date":80,"medical_device_id":20,"response_letter_date":20},452,[61,62,63,64,65,13,13,13],"\u003Ctime datetime=\"2025-11-25T05:00:00Z\">11\u002F25\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-10-30T04:00:00Z\">10\u002F30\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fowen-biosciences-inc-710275-10302025\">Owen Biosciences, Inc. \u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-11\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Dr. Donald R. Owen\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Owen Biosciences, Inc. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>7053 Revenue Drive\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Baton Rouge\u003C\u002Fspan>, \u003Cspan>LA\u003C\u002Fspan> \u003Cspan>70809-4918\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-11\u003C\u002Fp>\u003Cp>October 30, 2025\u003C\u002Fp>\u003Cp>Dear Dr. Owen:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Owen Biosciences, Inc., FEI 1000132299, at 7053 Revenue Drive, Baton Rouge, from March 25 to 27, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21, Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your April 10, 2025 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications designed to assure drug products conform to appropriate standards of identity, strength, quality, and purity. Your firm also failed to have, for each batch of drug product, an appropriate laboratory determination of satisfactory conformance to final specifications for drug products prior to release (21 CFR 211.160(b) and 211.165(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactures various topical over-the-counter (OTC) drug products, including those containing the active ingredient benzoyl peroxide. There is a known degradation mechanism of benzoyl peroxide, under certain conditions, to form benzene, a known carcinogen. Your firm failed to establish scientifically sound and appropriate finished product specifications and failed to conduct benzene testing on your OTC topical drug products prior to release. For example, you manufactured and released at least \u003Cstrong>(b)(4)\u003C\u002Fstrong> lots of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> 2.5% benzoyl peroxide acne lotion without testing for benzene. FDA laboratory analysis of one lot of \u003Cstrong>(b)(4)\u003C\u002Fstrong> 2.5% benzoyl peroxide acne lotion your firm manufactured and distributed yielded excessive benzene levels of more than 20 parts per million (ppm). You failed to ensure that your drug products do not contain unacceptable benzene impurity levels.\u003C\u002Fp>\u003Cp>During the inspection, you informed our investigator that a retain sample of the FDA-tested lot as well as other lots manufactured of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> 2.5% benzoyl peroxide acne lotion were sent to a contract testing laboratory (CTL) to conduct impurity and assay testing.\u003C\u002Fp>\u003Cp>In your response, you mention that you will use a CTL to conduct benzene testing on the above-mentioned drug product. However, it is not clear if benzene testing will be performed on all lots prior to release. Your response also states that you are not aware of any FDA guideline on benzene testing, but FDA has alerted drug manufacturers of products at risk for presence of benzene that they should be testing those drug products for benzene. For more information see https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fpharmaceutical-quality-resources\u002Ffda-alerts-drug-manufacturers-risk-benzene-contamination-certain-drugs.\u003C\u002Fp>\u003Cp>Your response is inadequate because it does not detail any retrospective risk assessments (e.g., the actions that you will take) should any of the lots sent to your CTL for testing yield unacceptable benzene impurity levels. Further, your response lacks information that your CTL is qualified to test your drug products for benzene.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A list of chemical and microbial specifications, including test methods, used to analyze each lot of your drug product before a lot disposition decision.\u003C\u002Fli>\u003Cli>A detailed description of the method you establish to test for benzene in finished products prior to release.\u003C\u002Fli>\u003Cli>An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all lots of drug product distributed to the United States that are within expiry as of the date of this letter.\u003C\u002Fli>\u003Cli>A summary of all results obtained from testing retain samples from each lot of benzoyl peroxide products that are currently on the U.S. market within expiry. If the testing reveals substandard-quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to establish an adequate written testing program designed to assess the stability characteristics of drug products (21 CFR 211.166(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your stability program was not adequate to ensure that the OTC drug products you manufacture maintain their identity, strength, quality, purity, and safety throughout their shelf lives. For example, full shelf-life studies were not conducted for the entire stated expiry period. Additionally, the studies performed lacked adequate identity, microbiological, and impurities testing.\u003C\u002Fp>\u003Cp>Your response is inadequate because it fails to include sufficient details on your stability program, including how you will ensure adequate ongoing stability testing with scientific justification. Additionally, it does not include a retrospective risk assessment or information on how you will ensure marketed drug products meet stability specifications throughout shelf life.\u003C\u002Fp>\u003Cp>In your response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment and corrective action and preventive action (CAPA) plan to ensure the adequacy of your stability program. Your remediated program should include but not be limited to:\u003Cbr>o Validated stability-indicating methods.\u003Cbr>o Stability studies for each drug product in its marketed container-closure system before distribution is permitted.\u003Cbr>o An ongoing program in which representative lots of each product are added each year to the program to determine if the shelf-life claim remains valid.\u003Cbr>o Detailed definition of the specific attributes to be tested at each station (timepoint). Given that benzene is a known degradant of benzoyl peroxide and FDA analysis yielded excessive levels of benzene in your drug product, include benzene testing at each stability timepoint.\u003C\u002Fli>\u003Cli>All procedures that describe these and other elements of your remediated stability program.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your quality unit (QU) is inadequate. Your QU did not provide adequate oversight for the manufacture of your OTC drug products. For example, your QU failed to ensure:\u003C\u002Fp>\u003Cul>\u003Cli>Review of production and control records to ensure completeness and accuracy (21 CFR 211.192).\u003C\u002Fli>\u003Cli>Adequate written procedures to document and investigate any unexplained discrepancy or failure of a batch or any of its components to meet any specifications (21 CFR 211.22(d); 21 CFR 211.192).\u003C\u002Fli>\u003Cli>Appropriate change control procedures were followed related to drug product manufacturing (21 CFR 211.22(d)).\u003C\u002Fli>\u003Cli>Performance of periodic (i.e., at least annual) product review (21 CFR 211.180(e)).\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In your response, you state that you will address nonconforming products by quarantining the products and taking action to eliminate detected nonconformity. You also state that you will “follow the annual review of products,” identify nonconforming products, and make any necessary adjustments with supporting documentation.\u003C\u002Fp>\u003Cp>Your response is inadequate. You do not adequately detail how your quality function plans to improve its oversight of manufacturing quality. You also fail to assess the effects that your insufficient QU oversight had on product quality.\u003C\u002Fp>\u003Cp>Your QU is responsible for fully exercising its authority and responsibilities. FDA is concerned that your QU may not be conducting appropriate oversight regarding CGMP operations.\u003C\u002Fp>\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload for help with implementing quality systems and risk-management approaches to meet the requirements of CGMP regulations in 21 CFR 210 and 211.\u003C\u002Fp>\u003Cp>\u003Cstrong>Failed Commitment to Recall Contaminated Drug Lot\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA sampled and tested one lot of Benzoyl Peroxide Acne Lotion that is used as part of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Acne System Kit. On March 4, 2025, FDA held a teleconference with the drug product distributor, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, to recommend removal of this product lot from the U.S. market because it contained excessive benzene impurity levels of more than 20 ppm. During that call and again on March 5, 2025, \u003Cstrong>(b)(4)\u003C\u002Fstrong> communicated that it would voluntarily recall the product containing the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Benzoyl Peroxide Acne Lotion that FDA tested. However, neither Owen Biosciences, Inc. nor \u003Cstrong>(b)(4)\u003C\u002Fstrong> recalled the product before it expired.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Responsibilities as a Contractor\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Drugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer. You are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&amp;C Act for safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to adequately address this matter may lead to regulatory or legal action without further notice including, without limitation, seizure and injunction. Other Federal agencies may take your compliance history into account when considering the award of contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may be cause for FDA to withhold issuance of Export Certificates. Any violations of CGMP requirements may also be cause for FDA to withhold approval of new applications or supplements listing your firm as a drug manufacturer. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 1000132299 and ATTN: Daniel W. Brisker.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>&nbsp;\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nReference #:\n\n320-26-11\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nDr. Donald R. Owen\n\nRecipient Title\n\nChief Executive Officer\n\nOwen Biosciences, Inc.\n\n7053 Revenue Drive\n\nBaton Rouge, LA 70809-4918\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-11\nOctober 30, 2025\nDear Dr. Owen:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Owen Biosciences, Inc., FEI 1000132299, at 7053 Revenue Drive, Baton Rouge, from March 25 to 27, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21, Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your April 10, 2025 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nCGMP Violations\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n1. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications designed to assure drug products conform to appropriate standards of identity, strength, quality, and purity. Your firm also failed to have, for each batch of drug product, an appropriate laboratory determination of satisfactory conformance to final specifications for drug products prior to release (21 CFR 211.160(b) and 211.165(a)).\nYour firm manufactures various topical over-the-counter (OTC) drug products, including those containing the active ingredient benzoyl peroxide. There is a known degradation mechanism of benzoyl peroxide, under certain conditions, to form benzene, a known carcinogen. Your firm failed to establish scientifically sound and appropriate finished product specifications and failed to conduct benzene testing on your OTC topical drug products prior to release. For example, you manufactured and released at least (b)(4) lots of the (b)(4) 2.5% benzoyl peroxide acne lotion without testing for benzene. FDA laboratory analysis of one lot of (b)(4) 2.5% benzoyl peroxide acne lotion your firm manufactured and distributed yielded excessive benzene levels of more than 20 parts per million (ppm). You failed to ensure that your drug products do not contain unacceptable benzene impurity levels.\nDuring the inspection, you informed our investigator that a retain sample of the FDA-tested lot as well as other lots manufactured of the (b)(4) 2.5% benzoyl peroxide acne lotion were sent to a contract testing laboratory (CTL) to conduct impurity and assay testing.\nIn your response, you mention that you will use a CTL to conduct benzene testing on the above-mentioned drug product. However, it is not clear if benzene testing will be performed on all lots prior to release. Your response also states that you are not aware of any FDA guideline on benzene testing, but FDA has alerted drug manufacturers of products at risk for presence of benzene that they should be testing those drug products for benzene. For more information see https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fpharmaceutical-quality-resources\u002Ffda-alerts-drug-manufacturers-risk-benzene-contamination-certain-drugs.\nYour response is inadequate because it does not detail any retrospective risk assessments (e.g., the actions that you will take) should any of the lots sent to your CTL for testing yield unacceptable benzene impurity levels. Further, your response lacks information that your CTL is qualified to test your drug products for benzene.\nIn response to this letter, provide:\nA list of chemical and microbial specifications, including test methods, used to analyze each lot of your drug product before a lot disposition decision.\nA detailed description of the method you establish to test for benzene in finished products prior to release.\nAn action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all lots of drug product distributed to the United States that are within expiry as of the date of this letter.\nA summary of all results obtained from testing retain samples from each lot of benzoyl peroxide products that are currently on the U.S. market within expiry. If the testing reveals substandard-quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\nA comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\n2. Your firm failed to establish an adequate written testing program designed to assess the stability characteristics of drug products (21 CFR 211.166(a)).\nYour stability program was not adequate to ensure that the OTC drug products you manufacture maintain their identity, strength, quality, purity, and safety throughout their shelf lives. For example, full shelf-life studies were not conducted for the entire stated expiry period. Additionally, the studies performed lacked adequate identity, microbiological, and impurities testing.\nYour response is inadequate because it fails to include sufficient details on your stability program, including how you will ensure adequate ongoing stability testing with scientific justification. Additionally, it does not include a retrospective risk assessment or information on how you will ensure marketed drug products meet stability specifications throughout shelf life.\nIn your response to this letter, provide:\nA comprehensive, independent assessment and corrective action and preventive action (CAPA) plan to ensure the adequacy of your stability program. Your remediated program should include but not be limited to:\no Validated stability-indicating methods.\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted.\no An ongoing program in which representative lots of each product are added each year to the program to determine if the shelf-life claim remains valid.\no Detailed definition of the specific attributes to be tested at each station (timepoint). Given that benzene is a known degradant of benzoyl peroxide and FDA analysis yielded excessive levels of benzene in your drug product, include benzene testing at each stability timepoint.\nAll procedures that describe these and other elements of your remediated stability program.\n3. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\nYour quality unit (QU) is inadequate. Your QU did not provide adequate oversight for the manufacture of your OTC drug products. For example, your QU failed to ensure:\nReview of production and control records to ensure completeness and accuracy (21 CFR 211.192).\nAdequate written procedures to document and investigate any unexplained discrepancy or failure of a batch or any of its components to meet any specifications (21 CFR 211.22(d); 21 CFR 211.192).\nAppropriate change control procedures were followed related to drug product manufacturing (21 CFR 211.22(d)).\nPerformance of periodic (i.e., at least annual) product review (21 CFR 211.180(e)).\nIn your response, you state that you will address nonconforming products by quarantining the products and taking action to eliminate detected nonconformity. You also state that you will “follow the annual review of products,” identify nonconforming products, and make any necessary adjustments with supporting documentation.\nYour response is inadequate. You do not adequately detail how your quality function plans to improve its oversight of manufacturing quality. You also fail to assess the effects that your insufficient QU oversight had on product quality.\nYour QU is responsible for fully exercising its authority and responsibilities. FDA is concerned that your QU may not be conducting appropriate oversight regarding CGMP operations.\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload for help with implementing quality systems and risk-management approaches to meet the requirements of CGMP regulations in 21 CFR 210 and 211.\nFailed Commitment to Recall Contaminated Drug Lot\nFDA sampled and tested one lot of Benzoyl Peroxide Acne Lotion that is used as part of the (b)(4) Acne System Kit. On March 4, 2025, FDA held a teleconference with the drug product distributor, (b)(4), to recommend removal of this product lot from the U.S. market because it contained excessive benzene impurity levels of more than 20 ppm. During that call and again on March 5, 2025, (b)(4) communicated that it would voluntarily recall the product containing the (b)(4) Benzoyl Peroxide Acne Lotion that FDA tested. However, neither Owen Biosciences, Inc. nor (b)(4) recalled the product before it expired.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nResponsibilities as a Contractor\nDrugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer. You are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&C Act for safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. Failure to adequately address this matter may lead to regulatory or legal action without further notice including, without limitation, seizure and injunction. Other Federal agencies may take your compliance history into account when considering the award of contracts.\nFailure to address violations may be cause for FDA to withhold issuance of Export Certificates. Any violations of CGMP requirements may also be cause for FDA to withhold approval of new applications or supplements listing your firm as a drug manufacturer. We may re-inspect to verify that you have completed corrective actions to address any violations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 1000132299 and ATTN: Daniel W. Brisker.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research","Owen Biosciences, Inc.","owen-biosciences-inc-710275-10302025","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fowen-biosciences-inc-710275-10302025","2026-10-26T08:09:39.713108+00:00","2025-11-25","710275","Drugs Over-the-Counter Drugs","Dr. Donald R. Owen","2026-08-19T13:26:35.546+00:00","VIA Electronic Mail","320-26-11","2025-10-30",{"id":82,"raw":83,"subject":89,"body_html":90,"body_text":91,"firm_name":92,"letter_id":93,"created_at":46,"fei_number":20,"letter_url":94,"updated_at":95,"action_type":23,"case_status":49,"posted_date":96,"marcs_cms_no":97,"product_type":52,"closeout_date":20,"issuing_office":87,"recipient_name":98,"body_fetched_at":99,"delivery_method":100,"recipient_title":20,"reference_number":20,"action_taken_date":101,"medical_device_id":20,"response_letter_date":20},1450,[84,85,86,87,88,13,13,13],"\u003Ctime datetime=\"2024-05-21T13:20:00Z\">05\u002F21\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-04-30T04:00:00Z\">04\u002F30\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fakan-biosciences-inc-654674-04302024\">Akan Biosciences, Inc.\u003C\u002Fa>","Office of Biological Products Operations – Division I","CGMP\u002FRegulations for Human Cells, Tissues &amp; Cellular Products (HCT\u002FPs)","CGMP\u002FRegulations for Human Cells, Tissues & Cellular Products (HCT\u002FPs)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mukesh NMI Kumar\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Akan Biosciences, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>610 Professional Drive, Ste 103\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Gaithersburg\u003C\u002Fspan>, \u003Cspan>MD\u003C\u002Fspan> \u003Cspan>20879-3460\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Biological Products Operations – Division I\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>April 30, 2024\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>24-654674\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Kumar,\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your firm, Akan Biosciences, Inc., located at 610 Professional Drive, Ste 103; Gaithersburg, MD 20879-3460 from September 20-30, 2022. During the inspection, an FDA investigator documented your manufacture of an adipose derived, stromal vascular fraction (SVF) cellular product for allogenic use with the brand name Ayama™ (hereinafter, also referred to as “your product”). The product’s labeling indicates it is sterile. You and your distributor, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, have distributed this product to practitioners and medical facilities throughout the United States.\u003C\u002Fp>\n\n\u003Cp>Information and records gathered prior to, during, and after the inspection, including information on your website, https:\u002F\u002Fakanbio.com\u002Fayama\u002F, reflect that your product is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or a condition in humans. For example, according to your website at https:\u002F\u002Fakanbio.com\u002Fayama\u002F (last visited April 2024), your product is an injectable product intended to “repair, reconstruct and replace your skin tissue”. Because these intended uses indicate that your product is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, your product is a drug as defined in section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) [21 U.S.C. § 321(g)(1)(B)]. Your product is also a drug under section 201(g)(1)(C) of the FD&amp;C Act because it is intended to affect the structure or any function of the body. Your product is also a biological product as defined in section 351(i) of the Public Health Service Act (PHS Act) [42 U.S.C. § 262(i)] because it is applicable to the prevention, treatment, or cure of a disease or condition of human beings.\u003C\u002Fp>\n\n\u003Cp>Your product is also a human cell, tissue, or cellular or tissue-based product (HCT\u002FP) as defined in 21 CFR 1271.3(d) and is subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act [42 U.S.C. § 264]. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act [42 U.S.C. § 264] and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act, and are subject to additional regulation, including appropriate premarket review.\u003C\u002Fp>\n\n\u003Cp>Akan Biosciences, Inc. does not qualify for any exception in 21 CFR 1271.15, and your product fails to meet all the criteria in 21 CFR 1271.10(a). Specifically, your product fails to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because your processing alters the original relevant characteristics of the adipose tissue related to its utility for reconstruction, repair, or replacement.\u003C\u002Fp>\n\n\u003Cp>In addition, your product fails to meet the criterion in 21 CFR 1271.10(a)(2) that the HCT\u002FPs be “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer’s objective intent.” Your product is not intended to perform the same basic function or functions of adipose tissue in the recipient as in the donor, such as cushioning and support for other tissues, including the skin and internal organs, storing energy in the form of lipids, and insulating the body, among other functions. Using your product for the repair, reconstruction, and replacement of skin tissue, for example, is not homologous use as defined in 21 CFR 1271.3(c).\u003C\u002Fp>\n\n\u003Cp>Therefore, your product is not regulated solely under section 361 of the PHS Act [42 U.S.C. § 264] and the regulations in 21 CFR Part 1271. Because your product does not meet all the criteria in 21 CFR 1271.10(a), and Akan Biosciences, Inc. does not qualify for any exception in 21 CFR 1271.15, your product is regulated as a drug as defined in section 201(g)(1)(B) of the FD&amp;C Act [21 U.S.C. § 321(g)(1)(B)] and a biological product as defined in section 351(i) of the PHS Act [42 U.S.C. § 262(i)].\u003C\u002Fp>\n\n\u003Cp>Be advised that to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. § 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations [21 U.S.C. § 355(i); 42 U.S.C. § 262(a)(3); 21 CFR Part 312]. Your product is not the subject of an approved biologics license application (BLA), nor is there an IND in effect for your product.\u003C\u002Fp>\n\n\u003Cp>Additionally, during the inspection, an FDA investigator documented significant violations for human cells, tissues, and cellular and tissue-based products (HCT\u002FPs) from 21 CFR 1271 and issued under the authority of Section 361 of the PHS Act [42 U.S.C. § 264]. Further, FDA investigators documented evidence of significant violations from current good manufacturing practice (CGMP) requirements, including violation of section 501(a)(2)(B) of the FD&amp;C Act [21 U.S.C. § 351(a)(2)(B)] and 21 CFR 210 and 211.\u003C\u002Fp>\n\n\u003Cp>The violations documented on the Form FDA-483, List of Inspectional Observations, were presented to and discussed with you at the conclusion of the inspection. Additional violations were noted upon further review of the records collected during the inspection. The violations, involving 585 vials of product manufactured between May 2021 and April 2022 from three donors, include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. \u003Cstrong>Failure to test a specimen from a donor of cells or tissue, whether viable or non-viable, for evidence of infection due to relevant communicable disease agents [21 CFR 1271.85(a)]\u003C\u002Fstrong>. For example, FDA has identified human immunodeficiency virus, type 1 (HIV-1), hepatitis C virus (HCV), and hepatitis B virus (HBV) as relevant communicable disease agents [21 CFR 1271.3(r)], and donors of HCT\u002FPs must be tested for such agents to adequately and appropriately reduce the risk of transmission of relevant communicable disease. The donor specimens collected from donors \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong> and \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong> were not tested for the antibody to hepatitis B core antigen (anti-HBc) and HIV-1, HCV, and HBV by the nucleic acid test (NAT) method. Such donors were not tested to adequately and appropriately reduce the risk of transmission of these diseases because NAT testing can detect evidence of infection at a significantly earlier stage than is possible under other tests. These donors were determined eligible on 3\u002F30\u002F2022 and 3\u002F31\u002F2022, respectively.\u003C\u002Fp>\n\n\u003Cp>2. \u003Cstrong>Failure to collect a donor specimen for testing for relevant communicable diseases at the time of recovery of cells or tissue from the donor or up to seven days before or after recovery [21 CFR 1271.80(b)]\u003C\u002Fstrong>. For example, HCT\u002FPs were recovered from donor \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong> on \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong>, however a donor specimen for testing was collected from the donor on \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong>, which is not within the required timeframe for collection of a specimen for testing.\u003C\u002Fp>\n\n\u003Cp>3. \u003Cstrong>Failure to test using appropriate FDA-licensed, approved or cleared donor screening tests, in accordance with the manufacturer’s instructions, to adequately and appropriately reduce the risk of transmission of relevant communicable disease agents or diseases [21 CFR 1271.80(c)]\u003C\u002Fstrong>. For example, the specimens for communicable disease testing, collected from donors \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong> and \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong>, were tested for the antibody to human immunodeficiency virus, types 1 and 2 (anti-HIV-1\u002F2), hepatitis B surface antigen (HBsAg), the antibody to hepatitis C virus (anti-HCV), and \u003Cem>Treponema pallidum\u003C\u002Fem> using test kits that were not FDA-licensed, approved, or cleared for donor screening. Donor \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong> was determined eligible on 3\u002F30\u002F2022. Donor \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong> was determined eligible on 3\u002F31\u002F2022.\u003C\u002Fp>\n\n\u003Cp>4. \u003Cstrong>Failure to screen a donor of cells or tissue by reviewing the donor’s relevant medical records for risk factors for, and clinical evidence of, relevant communicable disease agents and diseases [21 CFR 1271.75(a)(1)]\u003C\u002Fstrong>. For example:\u003Cbr>\na) Your Form, DS-01-02 (Version 1.0) \"Donor Screening Questionnaire,” is used as a relevant medical record to determine donor eligibility and was used to screen donors \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong> and \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong>. However, the form does not address certain risk factors for relevant communicable disease agents and diseases, including, for example, a donor’s risk of having West Nile Virus (WNV), among other risk factors.\u003C\u002Fp>\n\n\u003Cp>The following provides examples of conditions and behaviors that increase a donor’s relevant communicable disease risk. You should determine to be ineligible any potential donor who exhibits one or more of the following conditions or behaviors:\u003C\u002Fp>\n\n\u003Cp>i. Men who have had sex with another man in the preceding 5 years.\u003Cbr>\nii. Persons who have engaged in sex in exchange for money or drugs in the preceding 5 years. Your questionnaire only asks whether the donor has had “sexual contact with a prostitute or anyone else who takes money or drug or other payment for sex” in the past 12 months.\u003Cbr>\niii. Persons who have been in juvenile detention, lock up, jail or prison for more than 72 consecutive hours in the preceding 12 months.\u003Cbr>\niv. Persons who have had a past diagnosis of clinical, symptomatic viral hepatitis after their 11th birthday.\u003Cbr>\nv. Persons who have had a medical diagnosis or suspicion of WNV infection.\u003Cbr>\nvi. Persons who have tested positive or reactive for WNV infection using an FDA-licensed or investigational WNV NAT donor screening test in the preceding 120 days.\u003Cbr>\nvii. Persons who have been treated for or had syphilis within the preceding 12 months.\u003Cbr>\nviii. Persons who are at increased risk for Creutzfeldt-Jakob Disease (CJD) due to receiving a non-synthetic dura mater transplant, human pituitary-derived growth hormone, or having one or more blood relatives diagnosed with CJD.\u003Cbr>\nix. Persons with a medical diagnosis of Zika Virus (ZIKV) in the past 6 months.\u003Cbr>\nx. Persons who have engaged in sex within the past 6 months with a person who has residence in, or travel to, an area with an increased risk for ZIKV transmission.\u003Cbr>\nxi. Persons who have had a diagnosis with dementia or any degenerative or demyelinating disease of the central nervous system or other neurological disease of unknown etiology.\u003Cbr>\nxii. Persons who have had intimate contact with a xenotransplantation product recipient.\u003C\u002Fp>\n\n\u003Cp>b) A review of records for donor \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong> found that the donor did not complete a “Donor Screening Questionnaire” and was not screened for almost all risks of relevant communicable disease agents or diseases. From 4\u002F2022 to 7\u002F2022, you distributed \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;vials of Ayama™ that had been manufactured from 5\u002F27\u002F2021 to 4\u002F4\u002F2022 from adipose tissue recovered from donor \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>5. \u003Cstrong>Failure to clearly identify an HCT\u002FP that is in quarantine pending completion of a donor-eligibility determination and failure to ship HCT\u002FPs with the required accompanying records for which the donor eligibility determination has not been completed [21 CFR 1271.60(b) and (c)]\u003C\u002Fstrong>. For example, your firm distributed \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;vials&nbsp;of Ayama™ to \u003Cstrong>(b)(4)\u003C\u002Fstrong> physician\u002Fclinic locations in \u003Cstrong>(b)(4)\u003C\u002Fstrong> shipments between 4\u002F6\u002F2022 and 7\u002F5\u002F2022. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> vials were part of \u003Cstrong>(b)(4)\u003C\u002Fstrong> batch vials of Ayama™ manufactured from 5\u002F27-28\u002F2021 (\u003Cstrong>(b)(4)\u003C\u002Fstrong> batches, \u003Cstrong>(b)(4)\u003C\u002Fstrong> batch vials total) from adipose tissue recovered from donor \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong>. Donor screening and donor testing had not been completed for donor \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong>; therefore, a donor-eligibility determination had not been documented. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> vials of Ayama were not clearly identified as quarantined and were not accompanied by records stating that the product must not be implanted, transplanted, infused, or transferred until completion of donor eligibility determination.\u003C\u002Fp>\n\n\u003Cp>6. \u003Cstrong>Failure to ship in quarantine a pre-distribution shipment of HCT\u002FPs between establishments for which the pre-established criteria designed to prevent communicable disease transmission have not been documented as being met [21 CFR 1271.265(b)]\u003C\u002Fstrong>. For example, your firm delivered \u003Cstrong>(b)(4)\u003C\u002Fstrong> vials of Ayama™ (part of \u003Cstrong>(b)(4)\u003C\u002Fstrong> batch vials manufactured between 3\u002F31\u002F2022 and 4\u002F4\u002F2022 from adipose tissue recovered from donors \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong> and \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong>) to your distributor on 5\u002F11\u002F2022 that were not shipped in quarantine to prevent improper release. The products had not been determined to be available for distribution, as described in 21 CFR 1271.265(c), as there was no documentation that the pre-established criteria designed to prevent communicable disease transmission had been met.\u003C\u002Fp>\n\n\u003Cp>7. \u003Cstrong>Failure to establish written procedures for production and process control designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)]\u003C\u002Fstrong>. For example, your firm has not validated the manufacturing process for the adipose tissue product, Ayama™, with respect to identity, strength, quality and purity.\u003C\u002Fp>\n\n\u003Cp>8. \u003Cstrong>Failure to have an adequate system for monitoring environmental conditions in an aseptic processing area necessary to prevent contamination or mixups [21 CFR 211.42(c)(10)(iv)]\u003C\u002Fstrong>. For example,\u003Cbr>\na) You have not performed environmental monitoring of the aseptic processing area in association with each production run. You process batches on \u003Cstrong>(b)(4)\u003C\u002Fstrong> basis. However, SOP \u003Cstrong>(b)(4)\u003C\u002Fstrong> (Version 3, Effective date: August 8, 2020) indicates that “\u003Cstrong>(b)(4)\u003C\u002Fstrong> plates” sampling (i.e., contact plates and settle plates) for evaluation of viable microbial contamination of the biosafety cabinet will be performed \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Infrequent monitoring during production of the subject drug product may preclude identification of potential microbial contaminants that could adulterate your product.\u003C\u002Fp>\n\n\u003Cp>b) Your incubation conditions of \u003Cstrong>(b)(4)\u003C\u002Fstrong> plates used as contact plates and settle plates for environmental monitoring is not appropriate for the detection of viable microbial contamination. SOP \u003Cstrong>(b)(4)\u003C\u002Fstrong> (Version 3, Effective date: August 8, 2020) indicates that settle and contact plates should be incubated at \u003Cstrong>(b)(4)\u003C\u002Fstrong> for \u003Cstrong>(b)(4)\u003C\u002Fstrong> hours. Incubation at \u003Cstrong>(b)(4)\u003C\u002Fstrong> temperature for \u003Cstrong>(b)(4)\u003C\u002Fstrong> hours may exclude detection of certain microbial contaminants.\u003C\u002Fp>\n\n\u003Cp>We acknowledge receipt of your letter dated 10\u002F25\u002F2022, which provides a response and corrective actions to FDA’s inspectional observations (FDA-483). We have reviewed the corrective actions outlined in the response. We also acknowledge your voluntary product recall of Ayama™, initiated on 09\u002F29\u002F2022, as well as your commitment to correct firm operations and\u002For procedures involving donor eligibility (including donor screening\u002Ftesting); product quarantine; equipment calibration\u002Finspection; and labeling controls. However, we have determined that the response is inadequate to address our concerns regarding the above-noted violations as indicated below.\u003C\u002Fp>\n\n\u003Cp>21 CFR 211.100(a) requires written procedures for the production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess. Process validation studies determine whether \u003Cstrong>(b)(4)\u003C\u002Fstrong> state of control has been established while routine monitoring of process performance attributes determines whether control is maintained. Establishment of appropriate attributes and validation of processing method(s) of your sterile, allogeneic\u002Fnon-autologous, non-family related, HCT\u002FP product, Ayama,™ to be completed, approved, and documented prior to implementation of manufacturing operations, is essential for assuring product quality over the product lifecycle.\u003C\u002Fp>\n\n\u003Cp>According to your voluntary product recall documentation, you initiated a voluntary recall based upon available information regarding your product (i.e., associated deficiencies in donor screening processes affecting three batches sourced from two donors), although you “believe that no specific concerns existed for the safety of the product”. Your response to the FDA-483 states that you believe “the corrective and preventive actions taken by [you] adequately address the inspectional observations.” Regarding your responses to observations 4 and 5 (shipping under quarantine) and observation 7 (procedures appropriate to meet core CGTP requirements), we acknowledge that you have updated your donor eligibility determination criteria and procedures. These updated documents will be reviewed and verified during the next inspection of your establishment. However, your response does not provide sufficient information as well as corrective\u002Fpreventative actions such as:\u003C\u002Fp>\n\n\u003Cp>a) Your response lacks detail about remaining product on hand outside the recalled product and its disposition. Please identify all finished product produced, on-hand, and shipped as well as your intended disposition of this product.\u003C\u002Fp>\n\n\u003Cp>b) Your revised process validation report for Ayama lacks significant documentation to assure that the product has the identity, strength, purity, and quality it purports or is represented to possess. For example, it lacks donor eligibility information as well as full, proper validation (with approved protocol[s]) and approval of your processing methods (including test method suitability) for your sterile, HCT\u002FP product - Ayama™ in order to ensure your processing method:\u003Cbr>\n• reduces the risk of transmission of communicable disease by an HCT\u002FP (i.e., sterility); and\u003Cbr>\n• does not cause contamination or cross-contamination during processing; and prevents the introduction, transmission, or spread of communicable disease through the use of the HCT\u002FP.\u003C\u002Fp>\n\n\u003Cp>Neither this letter nor the observations noted on the Form FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of violations that may exist at your facilities. It is your responsibility to ensure full compliance with the FD&amp;C Act, PHS Act, and all applicable regulations. This letter notifies you of our findings and provides you an opportunity to address them. You should take prompt action to correct any violations and prevent their recurrence. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions include seizure and\u002For injunction.\u003C\u002Fp>\n\n\u003Cp>We request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you do not believe your products are in violation of the FD&amp;C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot address these matters completely within fifteen (15) working days, please explain the reason for your delay and the time frame for completion.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent via email to: Jason D. Abel, Compliance Officer, U.S. Food and Drug Administration, Office of Biological Products Operations – Division 1, email address: orabioinspectionalcorrespondence@fda.hhs.gov (Cc: Jason.Abel@fda.hhs.gov, please include firm name and FEI # within email subject line). If you have any questions, please contact Jason D. Abel via email.\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nSincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nMichael W. Roosevelt\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Biological Products Operations – Division I\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nMukesh NMI Kumar\n\nRecipient Title\n\nPresident\n\nAkan Biosciences, Inc.\n\n610 Professional Drive, Ste 103\n\nGaithersburg, MD 20879-3460\n\nUnited States\n\nIssuing Office:\n\nOffice of Biological Products Operations – Division I\n\nUnited States\n\nApril 30, 2024\n\nWARNING LETTER\n\n24-654674\n\nDear Mr. Kumar,\n\nThe United States Food and Drug Administration (FDA) conducted an inspection of your firm, Akan Biosciences, Inc., located at 610 Professional Drive, Ste 103; Gaithersburg, MD 20879-3460 from September 20-30, 2022. During the inspection, an FDA investigator documented your manufacture of an adipose derived, stromal vascular fraction (SVF) cellular product for allogenic use with the brand name Ayama™ (hereinafter, also referred to as “your product”). The product’s labeling indicates it is sterile. You and your distributor, (b)(4), have distributed this product to practitioners and medical facilities throughout the United States.\n\nInformation and records gathered prior to, during, and after the inspection, including information on your website, https:\u002F\u002Fakanbio.com\u002Fayama\u002F, reflect that your product is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or a condition in humans. For example, according to your website at https:\u002F\u002Fakanbio.com\u002Fayama\u002F (last visited April 2024), your product is an injectable product intended to “repair, reconstruct and replace your skin tissue”. Because these intended uses indicate that your product is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, your product is a drug as defined in section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. § 321(g)(1)(B)]. Your product is also a drug under section 201(g)(1)(C) of the FD&C Act because it is intended to affect the structure or any function of the body. Your product is also a biological product as defined in section 351(i) of the Public Health Service Act (PHS Act) [42 U.S.C. § 262(i)] because it is applicable to the prevention, treatment, or cure of a disease or condition of human beings.\n\nYour product is also a human cell, tissue, or cellular or tissue-based product (HCT\u002FP) as defined in 21 CFR 1271.3(d) and is subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act [42 U.S.C. § 264]. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act [42 U.S.C. § 264] and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act, and are subject to additional regulation, including appropriate premarket review.\n\nAkan Biosciences, Inc. does not qualify for any exception in 21 CFR 1271.15, and your product fails to meet all the criteria in 21 CFR 1271.10(a). Specifically, your product fails to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because your processing alters the original relevant characteristics of the adipose tissue related to its utility for reconstruction, repair, or replacement.\n\nIn addition, your product fails to meet the criterion in 21 CFR 1271.10(a)(2) that the HCT\u002FPs be “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer’s objective intent.” Your product is not intended to perform the same basic function or functions of adipose tissue in the recipient as in the donor, such as cushioning and support for other tissues, including the skin and internal organs, storing energy in the form of lipids, and insulating the body, among other functions. Using your product for the repair, reconstruction, and replacement of skin tissue, for example, is not homologous use as defined in 21 CFR 1271.3(c).\n\nTherefore, your product is not regulated solely under section 361 of the PHS Act [42 U.S.C. § 264] and the regulations in 21 CFR Part 1271. Because your product does not meet all the criteria in 21 CFR 1271.10(a), and Akan Biosciences, Inc. does not qualify for any exception in 21 CFR 1271.15, your product is regulated as a drug as defined in section 201(g)(1)(B) of the FD&C Act [21 U.S.C. § 321(g)(1)(B)] and a biological product as defined in section 351(i) of the PHS Act [42 U.S.C. § 262(i)].\n\nBe advised that to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. § 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations [21 U.S.C. § 355(i); 42 U.S.C. § 262(a)(3); 21 CFR Part 312]. Your product is not the subject of an approved biologics license application (BLA), nor is there an IND in effect for your product.\n\nAdditionally, during the inspection, an FDA investigator documented significant violations for human cells, tissues, and cellular and tissue-based products (HCT\u002FPs) from 21 CFR 1271 and issued under the authority of Section 361 of the PHS Act [42 U.S.C. § 264]. Further, FDA investigators documented evidence of significant violations from current good manufacturing practice (CGMP) requirements, including violation of section 501(a)(2)(B) of the FD&C Act [21 U.S.C. § 351(a)(2)(B)] and 21 CFR 210 and 211.\n\nThe violations documented on the Form FDA-483, List of Inspectional Observations, were presented to and discussed with you at the conclusion of the inspection. Additional violations were noted upon further review of the records collected during the inspection. The violations, involving 585 vials of product manufactured between May 2021 and April 2022 from three donors, include, but are not limited to, the following:\n\n1. Failure to test a specimen from a donor of cells or tissue, whether viable or non-viable, for evidence of infection due to relevant communicable disease agents [21 CFR 1271.85(a)]. For example, FDA has identified human immunodeficiency virus, type 1 (HIV-1), hepatitis C virus (HCV), and hepatitis B virus (HBV) as relevant communicable disease agents [21 CFR 1271.3(r)], and donors of HCT\u002FPs must be tested for such agents to adequately and appropriately reduce the risk of transmission of relevant communicable disease. The donor specimens collected from donors (b)(6), (b)(7)(C) and (b)(6), (b)(7)(C) were not tested for the antibody to hepatitis B core antigen (anti-HBc) and HIV-1, HCV, and HBV by the nucleic acid test (NAT) method. Such donors were not tested to adequately and appropriately reduce the risk of transmission of these diseases because NAT testing can detect evidence of infection at a significantly earlier stage than is possible under other tests. These donors were determined eligible on 3\u002F30\u002F2022 and 3\u002F31\u002F2022, respectively.\n\n2. Failure to collect a donor specimen for testing for relevant communicable diseases at the time of recovery of cells or tissue from the donor or up to seven days before or after recovery [21 CFR 1271.80(b)]. For example, HCT\u002FPs were recovered from donor (b)(6), (b)(7)(C) on (b)(6), (b)(7)(C), however a donor specimen for testing was collected from the donor on (b)(6), (b)(7)(C), which is not within the required timeframe for collection of a specimen for testing.\n\n3. Failure to test using appropriate FDA-licensed, approved or cleared donor screening tests, in accordance with the manufacturer’s instructions, to adequately and appropriately reduce the risk of transmission of relevant communicable disease agents or diseases [21 CFR 1271.80(c)]. For example, the specimens for communicable disease testing, collected from donors (b)(6), (b)(7)(C) and (b)(6), (b)(7)(C), were tested for the antibody to human immunodeficiency virus, types 1 and 2 (anti-HIV-1\u002F2), hepatitis B surface antigen (HBsAg), the antibody to hepatitis C virus (anti-HCV), and Treponema pallidum using test kits that were not FDA-licensed, approved, or cleared for donor screening. Donor (b)(6), (b)(7)(C) was determined eligible on 3\u002F30\u002F2022. Donor (b)(6), (b)(7)(C) was determined eligible on 3\u002F31\u002F2022.\n\n4. Failure to screen a donor of cells or tissue by reviewing the donor’s relevant medical records for risk factors for, and clinical evidence of, relevant communicable disease agents and diseases [21 CFR 1271.75(a)(1)]. For example:\n\na) Your Form, DS-01-02 (Version 1.0) \"Donor Screening Questionnaire,” is used as a relevant medical record to determine donor eligibility and was used to screen donors (b)(6), (b)(7)(C) and (b)(6), (b)(7)(C). However, the form does not address certain risk factors for relevant communicable disease agents and diseases, including, for example, a donor’s risk of having West Nile Virus (WNV), among other risk factors.\n\nThe following provides examples of conditions and behaviors that increase a donor’s relevant communicable disease risk. You should determine to be ineligible any potential donor who exhibits one or more of the following conditions or behaviors:\n\ni. Men who have had sex with another man in the preceding 5 years.\n\nii. Persons who have engaged in sex in exchange for money or drugs in the preceding 5 years. Your questionnaire only asks whether the donor has had “sexual contact with a prostitute or anyone else who takes money or drug or other payment for sex” in the past 12 months.\n\niii. Persons who have been in juvenile detention, lock up, jail or prison for more than 72 consecutive hours in the preceding 12 months.\n\niv. Persons who have had a past diagnosis of clinical, symptomatic viral hepatitis after their 11th birthday.\n\nv. Persons who have had a medical diagnosis or suspicion of WNV infection.\n\nvi. Persons who have tested positive or reactive for WNV infection using an FDA-licensed or investigational WNV NAT donor screening test in the preceding 120 days.\n\nvii. Persons who have been treated for or had syphilis within the preceding 12 months.\n\nviii. Persons who are at increased risk for Creutzfeldt-Jakob Disease (CJD) due to receiving a non-synthetic dura mater transplant, human pituitary-derived growth hormone, or having one or more blood relatives diagnosed with CJD.\n\nix. Persons with a medical diagnosis of Zika Virus (ZIKV) in the past 6 months.\n\nx. Persons who have engaged in sex within the past 6 months with a person who has residence in, or travel to, an area with an increased risk for ZIKV transmission.\n\nxi. Persons who have had a diagnosis with dementia or any degenerative or demyelinating disease of the central nervous system or other neurological disease of unknown etiology.\n\nxii. Persons who have had intimate contact with a xenotransplantation product recipient.\n\nb) A review of records for donor (b)(6), (b)(7)(C) found that the donor did not complete a “Donor Screening Questionnaire” and was not screened for almost all risks of relevant communicable disease agents or diseases. From 4\u002F2022 to 7\u002F2022, you distributed (b)(4) vials of Ayama™ that had been manufactured from 5\u002F27\u002F2021 to 4\u002F4\u002F2022 from adipose tissue recovered from donor (b)(6), (b)(7)(C).\n\n5. Failure to clearly identify an HCT\u002FP that is in quarantine pending completion of a donor-eligibility determination and failure to ship HCT\u002FPs with the required accompanying records for which the donor eligibility determination has not been completed [21 CFR 1271.60(b) and (c)]. For example, your firm distributed (b)(4) vials of Ayama™ to (b)(4) physician\u002Fclinic locations in (b)(4) shipments between 4\u002F6\u002F2022 and 7\u002F5\u002F2022. The (b)(4) vials were part of (b)(4) batch vials of Ayama™ manufactured from 5\u002F27-28\u002F2021 ((b)(4) batches, (b)(4) batch vials total) from adipose tissue recovered from donor (b)(6), (b)(7)(C). Donor screening and donor testing had not been completed for donor (b)(6), (b)(7)(C); therefore, a donor-eligibility determination had not been documented. The (b)(4) vials of Ayama were not clearly identified as quarantined and were not accompanied by records stating that the product must not be implanted, transplanted, infused, or transferred until completion of donor eligibility determination.\n\n6. Failure to ship in quarantine a pre-distribution shipment of HCT\u002FPs between establishments for which the pre-established criteria designed to prevent communicable disease transmission have not been documented as being met [21 CFR 1271.265(b)]. For example, your firm delivered (b)(4) vials of Ayama™ (part of (b)(4) batch vials manufactured between 3\u002F31\u002F2022 and 4\u002F4\u002F2022 from adipose tissue recovered from donors (b)(6), (b)(7)(C) and (b)(6), (b)(7)(C)) to your distributor on 5\u002F11\u002F2022 that were not shipped in quarantine to prevent improper release. The products had not been determined to be available for distribution, as described in 21 CFR 1271.265(c), as there was no documentation that the pre-established criteria designed to prevent communicable disease transmission had been met.\n\n7. Failure to establish written procedures for production and process control designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)]. For example, your firm has not validated the manufacturing process for the adipose tissue product, Ayama™, with respect to identity, strength, quality and purity.\n\n8. Failure to have an adequate system for monitoring environmental conditions in an aseptic processing area necessary to prevent contamination or mixups [21 CFR 211.42(c)(10)(iv)]. For example,\n\na) You have not performed environmental monitoring of the aseptic processing area in association with each production run. You process batches on (b)(4) basis. However, SOP (b)(4) (Version 3, Effective date: August 8, 2020) indicates that “(b)(4) plates” sampling (i.e., contact plates and settle plates) for evaluation of viable microbial contamination of the biosafety cabinet will be performed (b)(4). Infrequent monitoring during production of the subject drug product may preclude identification of potential microbial contaminants that could adulterate your product.\n\nb) Your incubation conditions of (b)(4) plates used as contact plates and settle plates for environmental monitoring is not appropriate for the detection of viable microbial contamination. SOP (b)(4) (Version 3, Effective date: August 8, 2020) indicates that settle and contact plates should be incubated at (b)(4) for (b)(4) hours. Incubation at (b)(4) temperature for (b)(4) hours may exclude detection of certain microbial contaminants.\n\nWe acknowledge receipt of your letter dated 10\u002F25\u002F2022, which provides a response and corrective actions to FDA’s inspectional observations (FDA-483). We have reviewed the corrective actions outlined in the response. We also acknowledge your voluntary product recall of Ayama™, initiated on 09\u002F29\u002F2022, as well as your commitment to correct firm operations and\u002For procedures involving donor eligibility (including donor screening\u002Ftesting); product quarantine; equipment calibration\u002Finspection; and labeling controls. However, we have determined that the response is inadequate to address our concerns regarding the above-noted violations as indicated below.\n\n21 CFR 211.100(a) requires written procedures for the production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess. Process validation studies determine whether (b)(4) state of control has been established while routine monitoring of process performance attributes determines whether control is maintained. Establishment of appropriate attributes and validation of processing method(s) of your sterile, allogeneic\u002Fnon-autologous, non-family related, HCT\u002FP product, Ayama,™ to be completed, approved, and documented prior to implementation of manufacturing operations, is essential for assuring product quality over the product lifecycle.\n\nAccording to your voluntary product recall documentation, you initiated a voluntary recall based upon available information regarding your product (i.e., associated deficiencies in donor screening processes affecting three batches sourced from two donors), although you “believe that no specific concerns existed for the safety of the product”. Your response to the FDA-483 states that you believe “the corrective and preventive actions taken by [you] adequately address the inspectional observations.” Regarding your responses to observations 4 and 5 (shipping under quarantine) and observation 7 (procedures appropriate to meet core CGTP requirements), we acknowledge that you have updated your donor eligibility determination criteria and procedures. These updated documents will be reviewed and verified during the next inspection of your establishment. However, your response does not provide sufficient information as well as corrective\u002Fpreventative actions such as:\n\na) Your response lacks detail about remaining product on hand outside the recalled product and its disposition. Please identify all finished product produced, on-hand, and shipped as well as your intended disposition of this product.\n\nb) Your revised process validation report for Ayama lacks significant documentation to assure that the product has the identity, strength, purity, and quality it purports or is represented to possess. For example, it lacks donor eligibility information as well as full, proper validation (with approved protocol[s]) and approval of your processing methods (including test method suitability) for your sterile, HCT\u002FP product - Ayama™ in order to ensure your processing method:\n\n• reduces the risk of transmission of communicable disease by an HCT\u002FP (i.e., sterility); and\n\n• does not cause contamination or cross-contamination during processing; and prevents the introduction, transmission, or spread of communicable disease through the use of the HCT\u002FP.\n\nNeither this letter nor the observations noted on the Form FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of violations that may exist at your facilities. It is your responsibility to ensure full compliance with the FD&C Act, PHS Act, and all applicable regulations. This letter notifies you of our findings and provides you an opportunity to address them. You should take prompt action to correct any violations and prevent their recurrence. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions include seizure and\u002For injunction.\n\nWe request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you do not believe your products are in violation of the FD&C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot address these matters completely within fifteen (15) working days, please explain the reason for your delay and the time frame for completion.\n\nYour response should be sent via email to: Jason D. Abel, Compliance Officer, U.S. Food and Drug Administration, Office of Biological Products Operations – Division 1, email address: orabioinspectionalcorrespondence@fda.hhs.gov (Cc: Jason.Abel@fda.hhs.gov, please include firm name and FEI # within email subject line). If you have any questions, please contact Jason D. Abel via email.\n\nSincerely,\n\n\u002FS\u002F\n\nMichael W. Roosevelt\n\nProgram Division Director\n\nOffice of Biological Products Operations – Division I","Akan Biosciences, Inc.","akan-biosciences-inc-654674-04302024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fakan-biosciences-inc-654674-04302024","2026-10-26T08:07:51.818264+00:00","2024-05-21","654674","Mukesh NMI Kumar","2026-08-20T00:04:21.225+00:00","VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED","2024-04-30",{"id":103,"raw":104,"subject":109,"body_html":110,"body_text":111,"firm_name":112,"letter_id":113,"created_at":114,"fei_number":20,"letter_url":115,"updated_at":116,"action_type":23,"case_status":49,"posted_date":117,"marcs_cms_no":118,"product_type":119,"closeout_date":20,"issuing_office":108,"recipient_name":120,"body_fetched_at":121,"delivery_method":122,"recipient_title":20,"reference_number":20,"action_taken_date":123,"medical_device_id":20,"response_letter_date":20},1534,[105,106,107,108,109,13,13,13],"\u003Ctime datetime=\"2024-04-02T13:20:00Z\">04\u002F02\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-03-21T04:00:00Z\">03\u002F21\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fagena-bioscience-inc-665159-03212024\">Agena Bioscience, Inc.\u003C\u002Fa>","Center for Devices and Radiological Health","Medical Device\u002FAdulterated\u002FMisbranded\u002FLacks PMA and\u002For 510(k)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Roman Haehn\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Vice President and General Manager of Clinical Genomics\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Agena Bioscience, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4755 Eastgate Mall\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>San Diego\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92121\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Roman.Haehn@agenabio.com\"> Roman.Haehn@agenabio.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n     \n        \u003Cdd> Division of Medical Device and Radiological Health Operations West\u003C\u002Fdd>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS # 665159\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>March 21, 2024\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nDear Mr. Haehn,\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located at 4755 Eastgate Mall, San Diego, CA on June 7, 2023, through June 13, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is a manufacturer of the MassARRAY4 System (MA4) and the iPLEX HS chemistry panels including the iPLEX HS Colon Panel in vitro diagnostic (IVD) products. Based on the inspection and our review of your firm’s website, it appears the iPLEX HS Colon Panel intended for use with the MA4 is intended for clinical diagnostic use. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), this product is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>The evidence reveals that the iPLEX HS Colon Panel intended for use with the MA4 is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The device is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\u003C\u002Fp>\n\n\u003Cp>You currently have clearance for the Impact Dx™ Factor V Leiden and Factor II Genotyping Test on the IMPACT Dx™ System (K132978) under 21 CFR 864.7280 for the following indications:\u003C\u002Fp>\n\n\u003Cp>The IMPACT Dx™ Factor V Leiden and Factor II Genotyping Test is a qualitative in vitro diagnostic device intended for use in the detection and genotyping of a single point mutation (G1691A, referred to as the Factor V Leiden mutation or FVL) of the Factor V gene, located on Chromosome 1q23, and a single point mutation (G20210A) of the prothrombin gene (referred to as Factor II or FII), located on Chromosome 11p11-q12, from genomic DNA isolated from EDTA anti-coagulated human whole blood samples. The test is to be performed on the IMPACT Dx™ System and is indicated for use as an aid in diagnosis of patients with suspected thrombophilia.\u003C\u002Fp>\n\n\u003Cp>During the inspection, your firm’s Director of Regulatory and Quality made verbal statements to the FDA investigator that your firm no longer sells the cleared Impact Dx™ Factor V Leiden and Factor II Genotyping Test on the IMPACT Dx™ System and has since only marketed and distributed the MA4.\u003C\u002Fp>\n\n\u003Cp>Based on evidence obtained during the inspection and a review of your firm’s website the iPLEX HS Colon Panel intended for use with the MA4 appears intended for clinical diagnostic use. Such evidence includes:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Verbal statements made to the FDA investigator during the inspection on behalf of your firm by your firm’s Director of Regulatory and Quality indicating that your firm no longer sells the Impact Dx™ Factor V Leiden and Factor II Genotyping Test on the IMPACT Dx™ System (K132978) and has instead replaced it with a new system, the MA4, and admitting that your firm sells the MA4 and reagent panels to companies who analyze patient samples that are used for clinical diagnosis.\u003C\u002Fli>\n\t\u003Cli>Distribution records and a customer list obtained during inspection that indicates your firm shipped MA4 Systems and iPLEX HS Colon Panels to clinical testing laboratories.\u003C\u002Fli>\n\t\u003Cli>A customer notification your firm sent to customers dated June 1, 2021, regarding distributed iPLEX HS Colon Panels that alerted customers of an increase in false negative results of certain reagent lots and stated that Agena was taking steps “to not impact your laboratory workflow.” This customer notification was sent to a clinical hospital in Texas and there is no evidence that these reagents were intended for research use only.\u003C\u002Fli>\n\t\u003Cli>A copy of the iPLEX HS Panels User Guide obtained during inspection that included instructions for preparing and testing samples as well as instructions for interpreting iPLEX HS Reports including the iPLEX HS Colon Panel intended for use with the MA4.\u003C\u002Fli>\n\t\u003Cli>Your firm’s website (last accessed on March 20, 2024) includes product descriptions and statements that the iPLEX HS Colon Panel “enables tumor profiling studies of colorectal cancer specimens”, and that, with the iPLEX HS Colon Panel, users can “Detect more than 80 clinically relevant variants across BRAF, EGFR, KRAS, NRAS, and PIK3CA” and “Identify variants at as low as 1% variant allele frequency.” [https:\u002F\u002Fwww.agenabio.com\u002Fproducts\u002Fpanel\u002Fiplex-hs-colon-panel\u002F]\u003C\u002Fli>\n\t\u003Cli>Your firm’s website (last accessed on March 20, 2024) includes customer stories from clients of Agena that indicate your MA4 System is intended for clinical diagnostic use. For instance, on the “FEATURED CUSTOMER STORIES” page, a portion of a testimonial reads, “Accurate, Cost-effective Newborn Screening for the Illinois Department of Health on the MassARRAY [MA4]…” And a statement from your CEO reads, “We are proud to have the MassARRAY System [MA4] chosen to be an integral part of one of the top newborn screening programs in the country…” [https:\u002F\u002Fwww.agenabio.com\u002Fstories\u002Fhgt\u002Faccurate-cost-effective-cftr-variant-detection-newborn-screening\u002F]. Another customer story comes from a client that is identified as a hospital system that uses your MA4 and iPLEX HS chemistry panels in tumor profiling and can deliver a quick and cost-effective test for clinically informative variants with a statement that other labs should explore the MassARRAY (MA4) for rapid, low-cost tumor profiling panels with a link to a product page for the iPLEX HS Colon Panel. [https:\u002F\u002Fwww.agenabio.com\u002Fstories\u002Fonc\u002Fmassarray-enables-sensitivity-quick-turnaround-tumor-profiling-bsw\u002F].\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your firm’s Director of Regulatory and Quality indicated that your firm markets the MA4 as a research use only (RUO) product and that your firm sells and distributes the MA4 to both research and clinical diagnostic companies. Your firm’s Director of Regulatory and Quality also indicated that labeling distributed with your MA4 products, and the labeling obtained during the inspection for your iPLEX HS Colon Panel, included the statement that these devices are “For Research Use Only. Not for use in diagnostic procedures.” Your firm’s website also includes the statement that these devices are “For Research Use Only. Not for use in diagnostic procedures.” But, as discussed in this letter, on numerous occasions your iPLEX HS Colon Panel and your MA4 were not being shipped or delivered for an investigation (21 CFR 809.10(c)). And these devices were not for use in the laboratory research phase of development but rather were represented as effective IVDs (21 CFR 809.10(c)(2)(i)). Your disclaimers that the MA4 and your iPLEX HS Colon Panel are intended for research use only (RUO) are inconsistent with the evidence obtained during the inspection and statements identified on your firm’s website as identified above and FDA has determined that your MA4 and iPLEX HS Colon Panel are intended for clinical diagnostic use.\u003C\u002Fp>\n\n\u003Cp>Your iPLEX HS Colon Panel intended for use with the MA4 appears to be a tumor profiling test intended for the diagnosis of colorectal cancer. You were required to submit to FDA a 510(k) for this device, because it either is a new device (21 CFR 807.81(a)(1)) or, if your iPLEX HS Colon Panel intended for use with the MA4 represents a change or modification from the device cleared in K132978 (which is indicated for use as an aid in diagnosis of patients with suspected thrombophilia), has been significantly changed or modified in design, components, method of manufacture, or intended use (21 CFR 807.81(a)(3)). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency [21 CFR 807.81(b)]. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at\u003Cbr>\nhttp:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that your firm’s iPLEX HS Colon Panel is misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals. Significant violations include, but are not limited to, failure to submit a written report to FDA of any correction or removal of a device initiated to reduce a risk to health posed by the device, as required by 21 CFR Part 806.10. For example:\u003C\u002Fp>\n\n\u003Cp>On June 1, 2021, your firm issued a Customer Notification alerting customers that certain lots of your iPLEX HS Colon v1.0 Panel did not include the A nucleotide termination in Well #8 which your firm determined could result in false negative results for three target variant alleles. Your firm instructed customers to not use the results for the impacted variants and that your firm would reformulate and verify the termination mix and provide further updates on availability. Your firm did not submit a written report of this removal to the agency, as required by 21 CFR 806.10.\u003C\u002Fp>\n\n\u003Cp>We request that your firm immediately cease any activities that result in the misbranding or adulteration of your devices. Your firm should take prompt action to address any violations. Failure to adequately address the matters discussed in this letter may result in legal action being initiated by the FDA without further notice. These actions may include, but are not necessarily limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the concerns noted in this letter. Include documentation of any corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for requiring additional time and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent to both: Jessica Mu, Director of Compliance Branch, at oradevices3firmresponse@fda.hhs.gov and to CDRHWarningLetterResponses@fda.hhs.gov. Refer to CMS # 665159 when replying. If you have any questions about the contents of this letter, please contact: Jeff R. Wooley, Compliance Officer, at 214-253-5251 or jeffrey.wooley@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of any deficiencies at your firm’s facility or associated with your firm’s devices. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific concerns noted in this letter may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Courtney Lias, Ph.D.\u003Cbr>\nActing Director\u003Cbr>\nOHT 7: Office of In Vitro Diagnostics\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Shari J. Shambaugh\u003Cbr>\nProgram Division Director, Division 3\u003Cbr>\nOffice of Medical Device and Radiological Health\u003Cbr>\nOffice of Regulatory Affairs\u003C\u002Fp>\n\n\u003Cp>&nbsp;\u003C\u002Fp>\n\n\u003Cp>CC: Glen Wise\u003Cbr>\nDirector, Quality and Regulatory\u003Cbr>\nGlenn.wise@agenabio.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nRoman Haehn\n\nRecipient Title\n\nVice President and General Manager of Clinical Genomics\n\nAgena Bioscience, Inc.\n\n4755 Eastgate Mall\n\nSan Diego, CA 92121\n\nUnited States\n\nRoman.Haehn@agenabio.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nSecondary Issuing Offices\n\nDivision of Medical Device and Radiological Health Operations West\n\nUnited States\n\nWARNING LETTER\n\nCMS # 665159\n\nMarch 21, 2024\n\nDear Mr. Haehn,\n\nDuring an inspection of your firm located at 4755 Eastgate Mall, San Diego, CA on June 7, 2023, through June 13, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is a manufacturer of the MassARRAY4 System (MA4) and the iPLEX HS chemistry panels including the iPLEX HS Colon Panel in vitro diagnostic (IVD) products. Based on the inspection and our review of your firm’s website, it appears the iPLEX HS Colon Panel intended for use with the MA4 is intended for clinical diagnostic use. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), this product is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\n\nThe evidence reveals that the iPLEX HS Colon Panel intended for use with the MA4 is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The device is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\n\nYou currently have clearance for the Impact Dx™ Factor V Leiden and Factor II Genotyping Test on the IMPACT Dx™ System (K132978) under 21 CFR 864.7280 for the following indications:\n\nThe IMPACT Dx™ Factor V Leiden and Factor II Genotyping Test is a qualitative in vitro diagnostic device intended for use in the detection and genotyping of a single point mutation (G1691A, referred to as the Factor V Leiden mutation or FVL) of the Factor V gene, located on Chromosome 1q23, and a single point mutation (G20210A) of the prothrombin gene (referred to as Factor II or FII), located on Chromosome 11p11-q12, from genomic DNA isolated from EDTA anti-coagulated human whole blood samples. The test is to be performed on the IMPACT Dx™ System and is indicated for use as an aid in diagnosis of patients with suspected thrombophilia.\n\nDuring the inspection, your firm’s Director of Regulatory and Quality made verbal statements to the FDA investigator that your firm no longer sells the cleared Impact Dx™ Factor V Leiden and Factor II Genotyping Test on the IMPACT Dx™ System and has since only marketed and distributed the MA4.\n\nBased on evidence obtained during the inspection and a review of your firm’s website the iPLEX HS Colon Panel intended for use with the MA4 appears intended for clinical diagnostic use. Such evidence includes:\n\nVerbal statements made to the FDA investigator during the inspection on behalf of your firm by your firm’s Director of Regulatory and Quality indicating that your firm no longer sells the Impact Dx™ Factor V Leiden and Factor II Genotyping Test on the IMPACT Dx™ System (K132978) and has instead replaced it with a new system, the MA4, and admitting that your firm sells the MA4 and reagent panels to companies who analyze patient samples that are used for clinical diagnosis.\n\nDistribution records and a customer list obtained during inspection that indicates your firm shipped MA4 Systems and iPLEX HS Colon Panels to clinical testing laboratories.\n\nA customer notification your firm sent to customers dated June 1, 2021, regarding distributed iPLEX HS Colon Panels that alerted customers of an increase in false negative results of certain reagent lots and stated that Agena was taking steps “to not impact your laboratory workflow.” This customer notification was sent to a clinical hospital in Texas and there is no evidence that these reagents were intended for research use only.\n\nA copy of the iPLEX HS Panels User Guide obtained during inspection that included instructions for preparing and testing samples as well as instructions for interpreting iPLEX HS Reports including the iPLEX HS Colon Panel intended for use with the MA4.\n\nYour firm’s website (last accessed on March 20, 2024) includes product descriptions and statements that the iPLEX HS Colon Panel “enables tumor profiling studies of colorectal cancer specimens”, and that, with the iPLEX HS Colon Panel, users can “Detect more than 80 clinically relevant variants across BRAF, EGFR, KRAS, NRAS, and PIK3CA” and “Identify variants at as low as 1% variant allele frequency.” [https:\u002F\u002Fwww.agenabio.com\u002Fproducts\u002Fpanel\u002Fiplex-hs-colon-panel\u002F]\n\nYour firm’s website (last accessed on March 20, 2024) includes customer stories from clients of Agena that indicate your MA4 System is intended for clinical diagnostic use. For instance, on the “FEATURED CUSTOMER STORIES” page, a portion of a testimonial reads, “Accurate, Cost-effective Newborn Screening for the Illinois Department of Health on the MassARRAY [MA4]…” And a statement from your CEO reads, “We are proud to have the MassARRAY System [MA4] chosen to be an integral part of one of the top newborn screening programs in the country…” [https:\u002F\u002Fwww.agenabio.com\u002Fstories\u002Fhgt\u002Faccurate-cost-effective-cftr-variant-detection-newborn-screening\u002F]. Another customer story comes from a client that is identified as a hospital system that uses your MA4 and iPLEX HS chemistry panels in tumor profiling and can deliver a quick and cost-effective test for clinically informative variants with a statement that other labs should explore the MassARRAY (MA4) for rapid, low-cost tumor profiling panels with a link to a product page for the iPLEX HS Colon Panel. [https:\u002F\u002Fwww.agenabio.com\u002Fstories\u002Fonc\u002Fmassarray-enables-sensitivity-quick-turnaround-tumor-profiling-bsw\u002F].\n\nYour firm’s Director of Regulatory and Quality indicated that your firm markets the MA4 as a research use only (RUO) product and that your firm sells and distributes the MA4 to both research and clinical diagnostic companies. Your firm’s Director of Regulatory and Quality also indicated that labeling distributed with your MA4 products, and the labeling obtained during the inspection for your iPLEX HS Colon Panel, included the statement that these devices are “For Research Use Only. Not for use in diagnostic procedures.” Your firm’s website also includes the statement that these devices are “For Research Use Only. Not for use in diagnostic procedures.” But, as discussed in this letter, on numerous occasions your iPLEX HS Colon Panel and your MA4 were not being shipped or delivered for an investigation (21 CFR 809.10(c)). And these devices were not for use in the laboratory research phase of development but rather were represented as effective IVDs (21 CFR 809.10(c)(2)(i)). Your disclaimers that the MA4 and your iPLEX HS Colon Panel are intended for research use only (RUO) are inconsistent with the evidence obtained during the inspection and statements identified on your firm’s website as identified above and FDA has determined that your MA4 and iPLEX HS Colon Panel are intended for clinical diagnostic use.\n\nYour iPLEX HS Colon Panel intended for use with the MA4 appears to be a tumor profiling test intended for the diagnosis of colorectal cancer. You were required to submit to FDA a 510(k) for this device, because it either is a new device (21 CFR 807.81(a)(1)) or, if your iPLEX HS Colon Panel intended for use with the MA4 represents a change or modification from the device cleared in K132978 (which is indicated for use as an aid in diagnosis of patients with suspected thrombophilia), has been significantly changed or modified in design, components, method of manufacture, or intended use (21 CFR 807.81(a)(3)). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency [21 CFR 807.81(b)]. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at\n\nhttp:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\n\nOur inspection also revealed that your firm’s iPLEX HS Colon Panel is misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals. Significant violations include, but are not limited to, failure to submit a written report to FDA of any correction or removal of a device initiated to reduce a risk to health posed by the device, as required by 21 CFR Part 806.10. For example:\n\nOn June 1, 2021, your firm issued a Customer Notification alerting customers that certain lots of your iPLEX HS Colon v1.0 Panel did not include the A nucleotide termination in Well #8 which your firm determined could result in false negative results for three target variant alleles. Your firm instructed customers to not use the results for the impacted variants and that your firm would reformulate and verify the termination mix and provide further updates on availability. Your firm did not submit a written report of this removal to the agency, as required by 21 CFR 806.10.\n\nWe request that your firm immediately cease any activities that result in the misbranding or adulteration of your devices. Your firm should take prompt action to address any violations. Failure to adequately address the matters discussed in this letter may result in legal action being initiated by the FDA without further notice. These actions may include, but are not necessarily limited to, seizure, injunction, and civil money penalties.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the concerns noted in this letter. Include documentation of any corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for requiring additional time and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent to both: Jessica Mu, Director of Compliance Branch, at oradevices3firmresponse@fda.hhs.gov and to CDRHWarningLetterResponses@fda.hhs.gov. Refer to CMS # 665159 when replying. If you have any questions about the contents of this letter, please contact: Jeff R. Wooley, Compliance Officer, at 214-253-5251 or jeffrey.wooley@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of any deficiencies at your firm’s facility or associated with your firm’s devices. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific concerns noted in this letter may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely,\n\n\u002FS\u002F\n\nCourtney Lias, Ph.D.\n\nActing Director\n\nOHT 7: Office of In Vitro Diagnostics\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\n\u002FS\u002F\n\nShari J. Shambaugh\n\nProgram Division Director, Division 3\n\nOffice of Medical Device and Radiological Health\n\nOffice of Regulatory Affairs\n\nCC: Glen Wise\n\nDirector, Quality and Regulatory\n\nGlenn.wise@agenabio.com","Agena Bioscience, Inc.","agena-bioscience-inc-665159-03212024","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fagena-bioscience-inc-665159-03212024","2026-10-26T08:07:51.129425+00:00","2024-04-02","665159","Medical Devices","Roman Haehn","2026-08-20T00:12:02.998+00:00","VIA UNITED PARCEL SERVICE","2024-03-21",{"id":125,"raw":126,"subject":131,"body_html":132,"body_text":133,"firm_name":134,"letter_id":135,"created_at":70,"fei_number":20,"letter_url":136,"updated_at":137,"action_type":23,"case_status":49,"posted_date":138,"marcs_cms_no":139,"product_type":140,"closeout_date":20,"issuing_office":130,"recipient_name":141,"body_fetched_at":142,"delivery_method":143,"recipient_title":20,"reference_number":20,"action_taken_date":144,"medical_device_id":20,"response_letter_date":20},22,[127,128,129,130,131,13,13,13],"\u003Ctime datetime=\"2026-07-21T04:00:00Z\">07\u002F21\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-06-05T04:00:00Z\">06\u002F05\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmineral-biosciences-llc-724745-06052026\">Mineral BioSciences, LLC \u003C\u002Fa>","Human Foods Program","Unapproved New Drugs\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Luke C. Blotsky\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Mineral BioSciences, LLC \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4050 S Sarival Ave\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Goodyear\u003C\u002Fspan>, \u003Cspan>AZ\u003C\u002Fspan> \u003Cspan>85338-3233\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Human Foods Program\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>June 5, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>CMS #724745\u003C\u002Fp>\u003Cp>Dear Mr. Blotsky:\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) conducted an inspection of your facility located at 4050 S Sarival Ave, Goodyear, AZ, on November 12-24, 2025. Based on inspectional findings and subsequent review of your websites https:\u002F\u002Fmineralbiosciences.com\u002F and https:\u002F\u002Fprotectcells.com\u002F, and your Facebook and Instagram social media pages at https:\u002F\u002Fwww.facebook.com\u002FProtectCells\u002F and https:\u002F\u002Fwww.instagram.com\u002Fp\u002FBYR6AmlDlx4\u002F, we have identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You can find the Act and FDA regulations through links on FDA's home page at www.fda.gov.\u003C\u002Fp>\u003Cp>At the conclusion of the inspection on November 24, 2025, our investigator provided you with a Form FDA 483, Inspectional Observations (FDA 483). We acknowledge receipt of your responses dated December 18, 2025, April 13, 2026, April 30, 2026, and May 1, 2026, and we address your responses below.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unapproved New Drugs\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA reviewed your websites at the Internet addresses https:\u002F\u002Fmineralbiosciences.com\u002F and https:\u002F\u002Fprotectcells.com\u002F in May 2026 and determined that you take orders on the website https:\u002F\u002Fprotectcells.com\u002F for your products Totala Fulvic Ionic Mineral Complex and Ionicell. We also reviewed your social media pages on Facebook (https:\u002F\u002Fwww.facebook.com\u002FProtectCells\u002F) and Instagram (https:\u002F\u002Fwww.instagram.com\u002Fp\u002FBYR6AmlDlx4\u002F) in March 2026, where you direct consumers to your website, https:\u002F\u002Fprotectcells.com\u002F, to purchase your products. Claims on your social media webpages establish that your Totala Fulvic Ionic Mineral Complex and Ionicell products are drugs under section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act.\u003C\u002Fp>\u003Cp>Examples of some of the claims that provide evidence that your products are intended for use as drugs include:\u003C\u002Fp>\u003Cul>\u003Cli>\u003Cu>Totala Fulvic Ionic Mineral Complex AND Ionicell\u003C\u002Fu>\u003Cbr>“Did you know Higher A1C levels are linked to diabetes complications? But did you also know that case reports have shown that Ioniplex can help control post-prandial blood sugar levels?” Note: Ioniplex is an ingredient in both the Totala and Ionicell products. (https:\u002F\u002Fwww.facebook.com\u002FProtectCells\u002F, from a post dated February 24, 2022)\u003C\u002Fli>\u003Cli>\u003Cu>Totala Fulvic Ionic Mineral Complex AND Ionicell\u003C\u002Fu>\u003Cbr>“Ioniplex has been clinically shown to repair and stimulate the body at the cellular level, leading to better glucose management.” Note: Ioniplex is an ingredient in both the Totala and Ionicell products. (https:\u002F\u002Fwww.facebook.com\u002FProtectCells\u002F, from a post dated January 29, 2021)\u003C\u002Fli>\u003Cli>\u003Cu>Totala Fulvic Ionic Mineral Complex\u003C\u002Fu>\u003Cbr>“[H]as been taking Totala … and has noticed not only a drop in his blood pressure, but less pain in his joints…” (https:\u002F\u002Fwww.instagram.com\u002Fp\u002FBYR6AmlDlx4\u002F, from a post dated February 23, 2018)\u003C\u002Fli>\u003Cli>\u003Cu>Ionicell\u003C\u002Fu>\u003Cbr>“[H]as been taking IoniCell for several weeks and has already noticed a drop in her daily glucose levels and fasting glucose levels.” (https:\u002F\u002Fwww.instagram.com\u002Fp\u002FBYR6AmlDlx4\u002F, from a post dated February 6, 2018)\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Misbranded Drugs\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\u003Cp>Your products Totala Fulvic Ionic Mineral Complex and Ionicell are intended for treatment or prevention of one or more diseases that are not amenable to self-diagnosis, treatment, or prevention without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, Totala Fulvic Ionic Mineral Complex and Ionicell fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)].\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Adulterated Dietary Supplements\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The inspection of your facility on November 12-24, 2025, identified serious violations of the FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, under Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111). These violations cause the Totala Fulvic Ionic Mineral Complex Lemon Lime and Ionicell dietary supplement products manufactured at your facility to be adulterated within the meaning of section 402(g)(1) of the Act [21 U.S.C. 342(g)(1)] because they have been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements. Thus, in addition to being unapproved new drugs and misbranded drugs, your Totala Fulvic Ionic Mineral Complex Lemon Lime and Ionicell products are also adulterated dietary supplements under section 402(g)(1) of the Act.\u003C\u002Fp>\u003Cp>Your significant violations of the CGMP requirements are as follows:\u003C\u002Fp>\u003Cp>1. You failed to meet sanitation requirements that apply to your physical plant and grounds under 21 CFR 111.15. Specifically:\u003C\u002Fp>\u003Cul>\u003Cli>You failed to maintain your physical plant in a clean and sanitary condition and in repair sufficient to prevent components, dietary supplements, or contact surfaces from becoming contaminated, as required by 21 CFR 111.15(b). For example, from November 12-13, 2025, our investigator observed insulation hanging from the ceiling, one light casing which appeared to be taped with water leaking from it, two holes in your wall exposing outside elements, and multiple doors, including bay doors, with opening gaps allowing light to shine into your facility.\u003C\u002Fli>\u003Cli>You failed to take effective measures to exclude pests from the physical plant and to protect against contamination of components, dietary supplements, and contact surfaces on the premises by pests, as required by 21 CFR 111.15(d)(2). For example, on November 13, 2025, our investigator reviewed your pest control records for April 2025 through November 2025 and observed several occasions in which a pest control technician documented interior stations with apparent rodent activity, including inside the \u003Cstrong>(b)(4)\u003C\u002Fstrong> room, \u003Cstrong>(b)(4)\u003C\u002Fstrong> room where finished products are stored, and in the ambient warehouse. In addition, our investigator observed multiple exit doors propped open to the outside.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>During the inspection, you stated that you would create a risk assessment based on your assessment of these observations and that you were already in the process of making certain changes, such as \u003Cstrong>(b)(4)\u003C\u002Fstrong>. We will evaluate the adequacy of your corrective actions during our next inspection.\u003C\u002Fp>\u003Cp>2. Your quality control personnel failed to approve or reject all processes, specifications, written procedures, controls, tests, and examinations, and deviations from or modifications to them, that may affect the identity, purity, strength, or composition of a dietary supplement, as required by 21 CFR 111.105(a). Specifically:\u003C\u002Fp>\u003Cul>\u003Cli>Your component specifications for \u003Cstrong>(b)(4)\u003C\u002Fstrong> had not been signed and approved by your quality control personnel.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>We have reviewed your responses to the FDA 483, dated December 18, 2025, and April 30, 2026, in which you stated that your raw material specifications will be signed, reviewed, and approved by quality control personnel. However, we are unable to evaluate the adequacy of your response because you did not provide documentation supporting that your quality control personnel have approved your raw material specifications.\u003C\u002Fp>\u003Cp>3. Your written batch production records (BPRs) did not include complete information relating to the production and control of each batch, as required by 21 CFR 111.255(b), because they did not include all information required to be in a BPR under 21 CFR 111.260. Specifically, your firm’s BPRs for the dietary supplement products Totala Fulvic Ionic Mineral Complex Lemon Lime and Ionicell did not include the following required information:\u003C\u002Fp>\u003Cul>\u003Cli>The time of the maintenance, cleaning, and sanitizing of the equipment and processing lines used in producing the batch, or a cross-reference to records where this information is retained. [21 CFR 111.260(c)]\u003C\u002Fli>\u003Cli>The initials of the person responsible for weighing or measuring each component used in the batch. [21 CFR 111.260(j)(2)(i)]\u003C\u002Fli>\u003Cli>The initials of the person responsible for verifying the weight or measure of each component used in the batch. [21 CFR 111.260(j)(2)(ii)]\u003C\u002Fli>\u003Cli>The initials of the person responsible for adding the component to the batch. [21 CFR 111.260(j)(2)(iii)]\u003C\u002Fli>\u003Cli>The initials of the person responsible for verifying the addition of components to the batch. [21 CFR 111.260(j)(2)(iv)].\u003C\u002Fli>\u003C\u002Ful>\u003Cp>We have reviewed your responses to the FDA 483, dated December 18, 2025, and April 30, 2026, in which you stated that the batch production records will be updated. However, we are unable to evaluate the adequacy of your response because you did not provide documentation supporting that your batch production records have been updated.\u003C\u002Fp>\u003Cp>4. Your firm failed to qualify certain suppliers by establishing the reliability of the suppliers’ certificates of analyses through confirmation of the results of the suppliers’ tests or examinations, in accordance with 21 CFR 111.75(a)(2)(ii)(A). Specifically, your firm relies on certificates of analyses to determine that component specifications for identity, purity, strength, composition, and limits on contamination are met, and you did not conduct testing on your \u003Cstrong>(b)(4)\u003C\u002Fstrong> dietary ingredients to establish the reliability of the suppliers’ certificates of analyses before use.\u003C\u002Fp>\u003Cp>We have reviewed your responses to the FDA 483, dated December 18, 2025, and April 30, 2026, in which you stated, “suppliers will be qualified establishing the reliability of the supplier’s certification of analysis through confirmation of the results of their tests or examinations.” On May 1, 2026, you provided component specification sheets that include instructions to confirm suppliers’ certificates of analyses with testing; however, we are unable to evaluate the adequacy of your response because you did not provide documentation supporting that the relevant suppliers have been qualified.\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>We also have the following comment:\u003C\u002Fp>\u003Cp>21 CFR 111.75(a)(2) does not allow firms to rely on a certificate of analysis to confirm the identity of a dietary ingredient. Rather, under 21 CFR 111.75(a)(1)(i), you must conduct at least one appropriate test or examination to verify the identity of any component that is a dietary ingredient, prior to using a component (or submit an exemption petition under 21 CFR 111.75(a)(2)(ii)). However, your component specification sheets submitted on May 1, 2026, for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> dietary ingredients state that component identity testing will be conducted \u003Cstrong>(b)(4)\u003C\u002Fstrong> instead of every time the component is used.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Your written reply should be directed to Rebecca Allen, Compliance Officer, United States Food and Drug Administration, Human Foods Program, Office of Enforcement, 5001 Campus Drive, College Park, Maryland 20740-3835 or via email at HFP-OCE-DietarySupplements@fda.hhs.gov. Please reference CMS #724745 on any submissions and within the subject line of any emails to us. If you have any questions, you may email at HFP-OCE-DietarySupplements@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Maria S. Knirk, JD, MBA\u003Cbr>Director, Office of Enforcement\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Human Foods Program\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Luke C. Blotsky\n\nRecipient Title\n\nCEO\n\nMineral BioSciences, LLC\n\n4050 S Sarival Ave\n\nGoodyear, AZ 85338-3233\n\nUnited States\n\nIssuing Office:\n\nHuman Foods Program\n\nUnited States\n\nJune 5, 2026\nWARNING LETTER\nCMS #724745\nDear Mr. Blotsky:\nThe U.S. Food and Drug Administration (FDA) conducted an inspection of your facility located at 4050 S Sarival Ave, Goodyear, AZ, on November 12-24, 2025. Based on inspectional findings and subsequent review of your websites https:\u002F\u002Fmineralbiosciences.com\u002F and https:\u002F\u002Fprotectcells.com\u002F, and your Facebook and Instagram social media pages at https:\u002F\u002Fwww.facebook.com\u002FProtectCells\u002F and https:\u002F\u002Fwww.instagram.com\u002Fp\u002FBYR6AmlDlx4\u002F, we have identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You can find the Act and FDA regulations through links on FDA's home page at www.fda.gov.\nAt the conclusion of the inspection on November 24, 2025, our investigator provided you with a Form FDA 483, Inspectional Observations (FDA 483). We acknowledge receipt of your responses dated December 18, 2025, April 13, 2026, April 30, 2026, and May 1, 2026, and we address your responses below.\nUnapproved New Drugs\nFDA reviewed your websites at the Internet addresses https:\u002F\u002Fmineralbiosciences.com\u002F and https:\u002F\u002Fprotectcells.com\u002F in May 2026 and determined that you take orders on the website https:\u002F\u002Fprotectcells.com\u002F for your products Totala Fulvic Ionic Mineral Complex and Ionicell. We also reviewed your social media pages on Facebook (https:\u002F\u002Fwww.facebook.com\u002FProtectCells\u002F) and Instagram (https:\u002F\u002Fwww.instagram.com\u002Fp\u002FBYR6AmlDlx4\u002F) in March 2026, where you direct consumers to your website, https:\u002F\u002Fprotectcells.com\u002F, to purchase your products. Claims on your social media webpages establish that your Totala Fulvic Ionic Mineral Complex and Ionicell products are drugs under section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act.\nExamples of some of the claims that provide evidence that your products are intended for use as drugs include:\nTotala Fulvic Ionic Mineral Complex AND Ionicell\n“Did you know Higher A1C levels are linked to diabetes complications? But did you also know that case reports have shown that Ioniplex can help control post-prandial blood sugar levels?” Note: Ioniplex is an ingredient in both the Totala and Ionicell products. (https:\u002F\u002Fwww.facebook.com\u002FProtectCells\u002F, from a post dated February 24, 2022)\nTotala Fulvic Ionic Mineral Complex AND Ionicell\n“Ioniplex has been clinically shown to repair and stimulate the body at the cellular level, leading to better glucose management.” Note: Ioniplex is an ingredient in both the Totala and Ionicell products. (https:\u002F\u002Fwww.facebook.com\u002FProtectCells\u002F, from a post dated January 29, 2021)\nTotala Fulvic Ionic Mineral Complex\n“[H]as been taking Totala … and has noticed not only a drop in his blood pressure, but less pain in his joints…” (https:\u002F\u002Fwww.instagram.com\u002Fp\u002FBYR6AmlDlx4\u002F, from a post dated February 23, 2018)\nIonicell\n“[H]as been taking IoniCell for several weeks and has already noticed a drop in her daily glucose levels and fasting glucose levels.” (https:\u002F\u002Fwww.instagram.com\u002Fp\u002FBYR6AmlDlx4\u002F, from a post dated February 6, 2018)\nYour products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\nMisbranded Drugs\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\nYour products Totala Fulvic Ionic Mineral Complex and Ionicell are intended for treatment or prevention of one or more diseases that are not amenable to self-diagnosis, treatment, or prevention without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, Totala Fulvic Ionic Mineral Complex and Ionicell fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)].\nAdulterated Dietary Supplements\nThe inspection of your facility on November 12-24, 2025, identified serious violations of the FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, under Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111). These violations cause the Totala Fulvic Ionic Mineral Complex Lemon Lime and Ionicell dietary supplement products manufactured at your facility to be adulterated within the meaning of section 402(g)(1) of the Act [21 U.S.C. 342(g)(1)] because they have been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements. Thus, in addition to being unapproved new drugs and misbranded drugs, your Totala Fulvic Ionic Mineral Complex Lemon Lime and Ionicell products are also adulterated dietary supplements under section 402(g)(1) of the Act.\nYour significant violations of the CGMP requirements are as follows:\n1. You failed to meet sanitation requirements that apply to your physical plant and grounds under 21 CFR 111.15. Specifically:\nYou failed to maintain your physical plant in a clean and sanitary condition and in repair sufficient to prevent components, dietary supplements, or contact surfaces from becoming contaminated, as required by 21 CFR 111.15(b). For example, from November 12-13, 2025, our investigator observed insulation hanging from the ceiling, one light casing which appeared to be taped with water leaking from it, two holes in your wall exposing outside elements, and multiple doors, including bay doors, with opening gaps allowing light to shine into your facility.\nYou failed to take effective measures to exclude pests from the physical plant and to protect against contamination of components, dietary supplements, and contact surfaces on the premises by pests, as required by 21 CFR 111.15(d)(2). For example, on November 13, 2025, our investigator reviewed your pest control records for April 2025 through November 2025 and observed several occasions in which a pest control technician documented interior stations with apparent rodent activity, including inside the (b)(4) room, (b)(4) room where finished products are stored, and in the ambient warehouse. In addition, our investigator observed multiple exit doors propped open to the outside.\nDuring the inspection, you stated that you would create a risk assessment based on your assessment of these observations and that you were already in the process of making certain changes, such as (b)(4). We will evaluate the adequacy of your corrective actions during our next inspection.\n2. Your quality control personnel failed to approve or reject all processes, specifications, written procedures, controls, tests, and examinations, and deviations from or modifications to them, that may affect the identity, purity, strength, or composition of a dietary supplement, as required by 21 CFR 111.105(a). Specifically:\nYour component specifications for (b)(4) had not been signed and approved by your quality control personnel.\nWe have reviewed your responses to the FDA 483, dated December 18, 2025, and April 30, 2026, in which you stated that your raw material specifications will be signed, reviewed, and approved by quality control personnel. However, we are unable to evaluate the adequacy of your response because you did not provide documentation supporting that your quality control personnel have approved your raw material specifications.\n3. Your written batch production records (BPRs) did not include complete information relating to the production and control of each batch, as required by 21 CFR 111.255(b), because they did not include all information required to be in a BPR under 21 CFR 111.260. Specifically, your firm’s BPRs for the dietary supplement products Totala Fulvic Ionic Mineral Complex Lemon Lime and Ionicell did not include the following required information:\nThe time of the maintenance, cleaning, and sanitizing of the equipment and processing lines used in producing the batch, or a cross-reference to records where this information is retained. [21 CFR 111.260(c)]\nThe initials of the person responsible for weighing or measuring each component used in the batch. [21 CFR 111.260(j)(2)(i)]\nThe initials of the person responsible for verifying the weight or measure of each component used in the batch. [21 CFR 111.260(j)(2)(ii)]\nThe initials of the person responsible for adding the component to the batch. [21 CFR 111.260(j)(2)(iii)]\nThe initials of the person responsible for verifying the addition of components to the batch. [21 CFR 111.260(j)(2)(iv)].\nWe have reviewed your responses to the FDA 483, dated December 18, 2025, and April 30, 2026, in which you stated that the batch production records will be updated. However, we are unable to evaluate the adequacy of your response because you did not provide documentation supporting that your batch production records have been updated.\n4. Your firm failed to qualify certain suppliers by establishing the reliability of the suppliers’ certificates of analyses through confirmation of the results of the suppliers’ tests or examinations, in accordance with 21 CFR 111.75(a)(2)(ii)(A). Specifically, your firm relies on certificates of analyses to determine that component specifications for identity, purity, strength, composition, and limits on contamination are met, and you did not conduct testing on your (b)(4) dietary ingredients to establish the reliability of the suppliers’ certificates of analyses before use.\nWe have reviewed your responses to the FDA 483, dated December 18, 2025, and April 30, 2026, in which you stated, “suppliers will be qualified establishing the reliability of the supplier’s certification of analysis through confirmation of the results of their tests or examinations.” On May 1, 2026, you provided component specification sheets that include instructions to confirm suppliers’ certificates of analyses with testing; however, we are unable to evaluate the adequacy of your response because you did not provide documentation supporting that the relevant suppliers have been qualified.\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\nWe also have the following comment:\n21 CFR 111.75(a)(2) does not allow firms to rely on a certificate of analysis to confirm the identity of a dietary ingredient. Rather, under 21 CFR 111.75(a)(1)(i), you must conduct at least one appropriate test or examination to verify the identity of any component that is a dietary ingredient, prior to using a component (or submit an exemption petition under 21 CFR 111.75(a)(2)(ii)). However, your component specification sheets submitted on May 1, 2026, for your (b)(4) dietary ingredients state that component identity testing will be conducted (b)(4) instead of every time the component is used.\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\nYour written reply should be directed to Rebecca Allen, Compliance Officer, United States Food and Drug Administration, Human Foods Program, Office of Enforcement, 5001 Campus Drive, College Park, Maryland 20740-3835 or via email at HFP-OCE-DietarySupplements@fda.hhs.gov. Please reference CMS #724745 on any submissions and within the subject line of any emails to us. If you have any questions, you may email at HFP-OCE-DietarySupplements@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nMaria S. Knirk, JD, MBA\nDirector, Office of Enforcement\nOffice of Compliance and Enforcement\nHuman Foods Program","Mineral BioSciences, LLC","mineral-biosciences-llc-724745-06052026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmineral-biosciences-llc-724745-06052026","2026-10-26T08:09:26.032125+00:00","2026-07-21","724745","Drugs","Mr. Luke C. Blotsky","2026-08-19T04:29:08.005+00:00","Via Email","2026-06-05",{"id":146,"raw":147,"subject":152,"body_html":153,"body_text":154,"firm_name":155,"letter_id":156,"created_at":157,"fei_number":20,"letter_url":158,"updated_at":159,"action_type":23,"case_status":49,"posted_date":160,"marcs_cms_no":161,"product_type":140,"closeout_date":20,"issuing_office":151,"recipient_name":162,"body_fetched_at":163,"delivery_method":55,"recipient_title":20,"reference_number":164,"action_taken_date":165,"medical_device_id":20,"response_letter_date":20},3164,[148,149,150,151,152,13,13,13],"\u003Ctime datetime=\"2021-09-07T13:20:00Z\">09\u002F07\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-08-26T04:00:00Z\">08\u002F26\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fkaleido-biosciences-inc-616026-08262021\">Kaleido Biosciences, Inc.\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","Bioresearch Monitoring Program","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>21-HFD-45-08-01\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Daniel Menichella\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Kaleido Biosciences, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>65 Hayden Avenue\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Lexington\u003C\u002Fspan>, \u003Cspan>MA\u003C\u002Fspan> \u003Cspan>02421-7994\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)\"> (b)(6)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Ref: 21-HFD-45-08-01\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Menichella:\u003C\u002Fp>\n\n\u003Cp>This Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted from February 24 to March 3, 2021. Investigator Kent A. Conforti, representing FDA, reviewed the role of Kaleido Biosciences, Inc. (Kaleido) as the sponsor of the following clinical investigations of the investigational drug KB109:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Protocol K031-120: “A Randomized, Open Label, Prospective, Parallel Group Study to Assess the Natural History of COVID-19\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> and Effects of KB109 in Addition to Supportive Self Care (SSC) Compared to SSC Alone on Measures of Health in Non-hospitalized Patients with Mild-to-Moderate COVID-19”\u003C\u002Fli>\n\t\u003Cli>Protocol K032-120: “An Exploratory, Open Label, Clinical Study to Evaluate the Physiologic Effects of KB109 in Adult Patients with Mild-to-Moderate COVID-19 on Gut Microbiota Structure and Function in the Outpatient Setting”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>This inspection was conducted as a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure that the rights, safety, and welfare of human subjects have been protected.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection, Investigator Conforti presented and discussed with your staff the Form FDA 483, Inspectional Observations. We acknowledge our receipt of Kaleido’s March 23, 2021, written response to the Form FDA 483.\u003C\u002Fp>\n\n\u003Cp>From our review of the FDA Establishment Inspection Report, the documents submitted with that report, and Kaleido’s March 23, 2021, written response to the Form FDA 483, it appears that Kaleido did not adhere to the applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) and applicable regulations contained in Title 21 of the Code of Federal Regulations, part 312 [21 CFR 312] governing the conduct of clinical investigations and the protection of human subjects. We wish to emphasize the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Failure to submit INDs for the conduct of clinical investigations with an investigational new drug that is subject to 21 CFR 312.2(a) [21 CFR 312.20(a), 312.20(b), and 312.40(a)].\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA regulations require a sponsor to submit, and to have in effect, an investigational new drug application (IND) before initiating a clinical investigation of a drug that is subject to 21 CFR 312.2(a) in human subjects, unless the clinical investigation qualifies for an IND exemption under 21 CFR 312.2 (see 21 CFR 312.20 and 312.40(a)). Kaleido failed to comply with these requirements. Specifically, Kaleido initiated and conducted the following clinical investigations of investigational drug products subject to section 505 of the FD&amp;C Act without submitting and having in effect an IND\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>The clinical investigation of the investigational drug KB109 conducted under Protocol K031-120\u003C\u002Fli>\n\t\u003Cli>The clinical investigation of the investigational drug KB109 conducted under Protocol K032-120\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>In Kaleido’s March 23, 2021, written response to the Form FDA 483, Kaleido argued that it was not obligated to submit an IND before initiating these clinical investigations because the article under study, KB109, was a food rather than a drug. Specifically, Kaleido argued that the investigations were conducted “to evaluate the effect of KB109 on the microbiome[,] as well as to determine the safety and tolerability of KB109 in the diseased population[,]” that is, human subjects with mild to moderate COVID-19, and thus it investigated KB109 for use as a food rather than a drug.\u003C\u002Fp>\n\n\u003Cp>To support this argument, Kaleido asserted that it did not intend for these “food studies” to evaluate whether KB109 would be an effective treatment or mitigation for COVID-19; rather, Kaleido argued that the secondary endpoints in these studies were determinative of safety and tolerability. For this reason, Kaleido stated that KB109 was a food intervention, and consistent with Agency guidance, it was appropriate to conduct these studies without an IND in a population with COVID-19.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>In further discussing the purported safety and tolerability endpoints of these two studies, Kaleido stated that because the medical community was still learning about risk factors for severe COVID-19, signs and symptoms of the disease were collected in both studies to support adequate safety monitoring, in order to capture signals of disease worsening that may warrant referral to emergency medical care. Kaleido argued that it collected information on symptoms related to worsening or improvement of disease conditions to determine if KB109 would have an impact on safety or tolerability in patients with COVID-19.\u003C\u002Fp>\n\n\u003Cp>Kaleido stated that the FD&amp;C Act specifically recognizes products used in the dietary management of a disease and subject to regulation as medical foods (when such products meet the definition of a medical food, comply with the requirements for medical foods, and are not subject to regulation as drugs). Although Kaleido did not explicitly argue that the clinical investigations were exempt from the IND requirement because they studied KB109 for use as a medical food, it did state that the findings from these studies could “enhance our understanding of the distinct nutritional requirements (DNR) that may exist in individuals with respiratory viral illnesses such as COVID-19 and would support the positioning of KB109 as a medical food.”\u003C\u002Fp>\n\n\u003Cp>In further arguing that its clinical investigations studied KB109’s use as a food, Kaleido stated that the Generally Recognized as Safe (GRAS) status of KB109 was determined by an outside firm that evaluated not only the composition of KB109, but also its consumption safety in patients with mild to moderate COVID-19. Kaleido asserted that this GRAS determination supported its conclusion that KB109 is a lawfully marketed food ingredient that could be evaluated in food studies such as Protocols K031-120 and K032-120.\u003C\u002Fp>\n\n\u003Cp>Finally, Kaleido stated that subjects were instructed to follow the Centers for Disease Control and Prevention (CDC) guidelines and supportive self-care (SSC) measures to manage COVID-19 symptoms, and argued that KB109 therefore was given for nutritional purposes and was not studied as a COVID-19 treatment.\u003C\u002Fp>\n\n\u003Cp>For the reasons described below, we conclude that the evidence collected during the inspection shows that KB109 was intended for use as a drug, not as a food, in the two clinical investigations named above.\u003C\u002Fp>\n\n\u003Cp>Section 201(g)(1) of the FD&amp;C Act [21 U.S.C. 321(g)(1)] defines \u003Cem>drug\u003C\u002Fem> as “articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals . . . .” Kaleido studied the efficacy and safety of KB109 to mitigate and treat COVID-19 in subjects who tested positive for COVID-19 as described below:\u003C\u002Fp>\n\n\u003Cp>As shown by the protocol, a published article supported by Kaleido, and Kaleido’s press releases, the objective of Protocol K031-120 was to compare the safety and efficacy of KB109 in combination with SSC under quarantine protocols set forth by the CDC, with SSC alone in human subjects with mild-to-moderate COVID-19. This study evaluated efficacy endpoints intended to assess KB109 for use in mitigating or treating COVID-19, including change from baseline in, and time to resolution of, overall composite and individual COVID-19-related symptom scores; time to resolution of fever; proportion of subjects with oxygen saturation &lt;95% and &lt;98%; and other endpoints, such as change from baseline in bedrest time, individual measures of quality of life (QOL), proportion of subjects with improvements in patient global impression on COVID-19 condition, proportion of subjects experiencing hospital admissions (all-cause and COVID-19-related), and number of healthcare utilizations.\u003C\u002Fp>\n\n\u003Cp>As shown by the protocol and a published article supported by Kaleido, the objective of Protocol K032-120 was to compare KB109, in combination with SSC under quarantine protocols set forth by the CDC or local ordinances and practices as advised by a healthcare provider, against SSC alone in human subjects with mild-to-moderate COVID-19. Physiologic effects were assessed by measuring biomarkers of inflammation and antibodies, physiologic responses of health in subjects, QOL, and hospital utilization. This study also assessed the effects of KB109 on the gut microbiome structure and function, and evaluated endpoints related to measures of health, as well as changes in laboratory measures, specific biomarkers, serology, and viral load in the presence and absence of KB109.\u003C\u002Fp>\n\n\u003Cp>For Protocol K031-120, the endpoints characterized in the protocol as secondary endpoints (for example, time to resolution of individual and composite COVID-19 symptoms, time to resolution of fever, and proportion of subjects hospitalized) clearly assessed the impact of KB109 on clinical manifestations of COVID-19 and were aligned with the recommended efficacy endpoints in published FDA guidances to aid sponsors in developing products to treat patients with COVID-19.\u003Csup>\u003Cem>\u003Cstrong>4, 5\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>For Protocol K032-120, while some endpoints could be considered safety outcomes that might be evaluated only to ensure that treatment with KB109 was not worsening the course of COVID-19, other endpoints (for example, proportion of subjects experiencing hospital admission during the follow-up period, measures of healthcare utilization, and proportion of subjects with oxygen saturation below normal) clearly assessed the use of KB109 in combination with SCC for the treatment or mitigation of COVID-19.\u003C\u002Fp>\n\n\u003Cp>We note that Kaleido itself described the purpose of KB109 in the clinical investigations conducted under Protocols K031-120 and K032-120 as “treatment of mild to moderate COVID-19” in a communication to FDA.\u003Csup>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>To the extent that Kaleido intended to argue that KB109 was used as a medical food in these clinical investigations, this argument fails for the following reasons:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A product is a medical food if it is “a food . . . intended for the specific dietary management of a disease or condition for which distinctive nutritional requirements, based on recognized scientific principles, are established by medical evaluation.”\u003Csup>\u003Cem>\u003Cstrong>7\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> No such distinctive nutritional requirements have been established for COVID-19. Dietary management of a disease is one way to treat or mitigate that disease; therefore, to the extent that a product that does not meet the medical food definition is intended for the dietary management of a disease, it is a drug under section 201(g)(1)(B) of the FD&amp;C Act.\u003C\u002Fli>\n\t\u003Cli>Even if there were distinctive nutritional requirements established for COVID-19, Protocols K031-120 and K032-120 went beyond “dietary management” of COVID-19 to evaluate KB109’s ability to treat COVID-19 by measuring the investigational product’s effects on fever, oxygen saturation, viral load, and other biomarkers of COVID-19 infection, among other things.\u003C\u002Fli>\n\t\u003Cli>Finally, the purported GRAS status of an article for one or more uses in food does not exempt the article from IND requirements when it is studied for use as a drug. In other words, an article may be a drug as used in a clinical trial, even if it is considered a food as used in other contexts. In addition, the instruction for subjects to adhere to CDC guidelines and SSC measures does not preclude investigating KB109 as an add-on therapy in the management of COVID-19 for subjects who are not at high risk for disease worsening or hospitalization.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>As Kaleido noted in its response to the Form FDA 483, whether an investigational article is a drug or a food depends on the intent of the investigation. Based on the study designs of Protocols K031-120 and K032-120, KB109 as used in these clinical investigations was a drug, per 201(g)(1) of the FD&amp;C Act, because KB109 was studied for use in the mitigation and treatment of COVID-19.\u003C\u002Fp>\n\n\u003Cp>Thus, before initiating the clinical investigations of KB109 conducted under Protocol K031- 120 and Protocol K032-120, Kaleido was required to submit an IND to FDA and to have an IND in effect under 21 CFR 312.40. FDA’s records indicate that Kaleido failed to submit an IND before conducting these clinical investigations, in which 350 human subjects were randomized at 16 clinical sites for Protocol K031-120, and 49 human subjects were randomized at 7 clinical sites for Protocol K032-120.\u003C\u002Fp>\n\n\u003Cp>In its response to the Form FDA 483, Kaleido stated that it is developing a procedure for determining the need for an IND (in consultation with FDA) when developing protocols for clinical studies in a disease population where endpoints may be viewed as diagnosing, mitigating, treating, preventing, or curing a disease. Kaleido’s corrective action plan does not provide sufficient details about its new procedure for IND determination. Without these details, we are unable to determine whether Kaleido’s corrective action plan is adequate to prevent similar violations in the future.\u003Cbr>\n\u003Cbr>\nThis letter is not intended to be an all-inclusive list of deficiencies with your clinical studies of an investigational drug. It is your responsibility to ensure adherence to each requirement of the law and relevant FDA regulations. You should address any deficiencies and establish procedures to ensure that any ongoing or future studies comply with FDA regulations.\u003C\u002Fp>\n\n\u003Cp>Within 15 business days of your receipt of this letter, you should notify this office in writing of the actions you have taken to prevent similar violations in the future. Failure to adequately address this matter may lead to regulatory action. If you believe you have complied with the FD&amp;C Act and relevant FDA regulations, please include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>If you have any questions, please call Miah Jung, Pharm.D., at 240-402-3728. Alternatively, you may e-mail FDA at CDER-OSI-Communications@fda.hhs.gov. Your written response and any pertinent documentation should be addressed to:\u003C\u002Fp>\n\n\u003Cp>Miah Jung, Pharm.D., M.S., RAC (US)\u003Cbr>\nBranch Chief (Acting)\u003Cbr>\nCompliance Enforcement Branch\u003Cbr>\nDivision of Enforcement and Postmarketing Safety\u003Cbr>\nOffice of Scientific Investigations\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\nBuilding 51, Room 5219\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>David C. Burrow, Pharm.D., J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Scientific Investigations\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nU.S. Food and Drug Administration\u003C\u002Fp>\n\n\u003Cp>_________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Coronavirus Disease 2019 (COVID-19) is the respiratory disease caused by the novel coronavirus called \u003Cem>Severe Acute Respiratory Syndrome Coronavirus 2\u003C\u002Fem> (SARS-CoV-2).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Also, neither of these clinical investigations qualified for any of the exemptions listed at 21 CFR 312.2 from the application of 21 CFR 312.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> \u003Cem>Guidance for Clinical Investigators, Sponsors, and IRBs: Investigational New Drug Applications (INDs) – Determining Whether Human Research Studies Can Be Conducted Without an IND, September 2013\u003C\u002Fem>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Guidance for industry \u003Cem>COVID-19: Developing Drugs and Biological Products for Treatment or Prevention\u003C\u002Fem> (May 2020; updated February 2021).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> Guidance for industry \u003Cem>Assessing COVID-19-Related Symptoms in Outpatient Adult and Adolescent Subjects in Clinical Trials of Drugs and Biological Products for COVID-19 Prevention or Treatment \u003C\u002Fem>(September 2020).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem> Pre-IND 151218 Type B Meeting Package for KB109, Kaleido Biosciences, Inc. (July 2, 2020).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>7\u003C\u002Fstrong>\u003C\u002Fem> 21 U.S.C. 360ee(b)(3).\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\n21-HFD-45-08-01\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nDaniel Menichella\n\nRecipient Title\n\nChief Executive Officer\n\nKaleido Biosciences, Inc.\n\n65 Hayden Avenue\n\nLexington, MA 02421-7994\n\nUnited States\n\n(b)(6)\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWARNING LETTER\n\nRef: 21-HFD-45-08-01\n\nDear Mr. Menichella:\n\nThis Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted from February 24 to March 3, 2021. Investigator Kent A. Conforti, representing FDA, reviewed the role of Kaleido Biosciences, Inc. (Kaleido) as the sponsor of the following clinical investigations of the investigational drug KB109:\n\nProtocol K031-120: “A Randomized, Open Label, Prospective, Parallel Group Study to Assess the Natural History of COVID-191 and Effects of KB109 in Addition to Supportive Self Care (SSC) Compared to SSC Alone on Measures of Health in Non-hospitalized Patients with Mild-to-Moderate COVID-19”\n\nProtocol K032-120: “An Exploratory, Open Label, Clinical Study to Evaluate the Physiologic Effects of KB109 in Adult Patients with Mild-to-Moderate COVID-19 on Gut Microbiota Structure and Function in the Outpatient Setting”\n\nThis inspection was conducted as a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure that the rights, safety, and welfare of human subjects have been protected.\n\nAt the conclusion of the inspection, Investigator Conforti presented and discussed with your staff the Form FDA 483, Inspectional Observations. We acknowledge our receipt of Kaleido’s March 23, 2021, written response to the Form FDA 483.\n\nFrom our review of the FDA Establishment Inspection Report, the documents submitted with that report, and Kaleido’s March 23, 2021, written response to the Form FDA 483, it appears that Kaleido did not adhere to the applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&C Act) and applicable regulations contained in Title 21 of the Code of Federal Regulations, part 312 [21 CFR 312] governing the conduct of clinical investigations and the protection of human subjects. We wish to emphasize the following:\n\nFailure to submit INDs for the conduct of clinical investigations with an investigational new drug that is subject to 21 CFR 312.2(a) [21 CFR 312.20(a), 312.20(b), and 312.40(a)].\n\nFDA regulations require a sponsor to submit, and to have in effect, an investigational new drug application (IND) before initiating a clinical investigation of a drug that is subject to 21 CFR 312.2(a) in human subjects, unless the clinical investigation qualifies for an IND exemption under 21 CFR 312.2 (see 21 CFR 312.20 and 312.40(a)). Kaleido failed to comply with these requirements. Specifically, Kaleido initiated and conducted the following clinical investigations of investigational drug products subject to section 505 of the FD&C Act without submitting and having in effect an IND2:\n\nThe clinical investigation of the investigational drug KB109 conducted under Protocol K031-120\n\nThe clinical investigation of the investigational drug KB109 conducted under Protocol K032-120\n\nIn Kaleido’s March 23, 2021, written response to the Form FDA 483, Kaleido argued that it was not obligated to submit an IND before initiating these clinical investigations because the article under study, KB109, was a food rather than a drug. Specifically, Kaleido argued that the investigations were conducted “to evaluate the effect of KB109 on the microbiome[,] as well as to determine the safety and tolerability of KB109 in the diseased population[,]” that is, human subjects with mild to moderate COVID-19, and thus it investigated KB109 for use as a food rather than a drug.\n\nTo support this argument, Kaleido asserted that it did not intend for these “food studies” to evaluate whether KB109 would be an effective treatment or mitigation for COVID-19; rather, Kaleido argued that the secondary endpoints in these studies were determinative of safety and tolerability. For this reason, Kaleido stated that KB109 was a food intervention, and consistent with Agency guidance, it was appropriate to conduct these studies without an IND in a population with COVID-19.3\n\nIn further discussing the purported safety and tolerability endpoints of these two studies, Kaleido stated that because the medical community was still learning about risk factors for severe COVID-19, signs and symptoms of the disease were collected in both studies to support adequate safety monitoring, in order to capture signals of disease worsening that may warrant referral to emergency medical care. Kaleido argued that it collected information on symptoms related to worsening or improvement of disease conditions to determine if KB109 would have an impact on safety or tolerability in patients with COVID-19.\n\nKaleido stated that the FD&C Act specifically recognizes products used in the dietary management of a disease and subject to regulation as medical foods (when such products meet the definition of a medical food, comply with the requirements for medical foods, and are not subject to regulation as drugs). Although Kaleido did not explicitly argue that the clinical investigations were exempt from the IND requirement because they studied KB109 for use as a medical food, it did state that the findings from these studies could “enhance our understanding of the distinct nutritional requirements (DNR) that may exist in individuals with respiratory viral illnesses such as COVID-19 and would support the positioning of KB109 as a medical food.”\n\nIn further arguing that its clinical investigations studied KB109’s use as a food, Kaleido stated that the Generally Recognized as Safe (GRAS) status of KB109 was determined by an outside firm that evaluated not only the composition of KB109, but also its consumption safety in patients with mild to moderate COVID-19. Kaleido asserted that this GRAS determination supported its conclusion that KB109 is a lawfully marketed food ingredient that could be evaluated in food studies such as Protocols K031-120 and K032-120.\n\nFinally, Kaleido stated that subjects were instructed to follow the Centers for Disease Control and Prevention (CDC) guidelines and supportive self-care (SSC) measures to manage COVID-19 symptoms, and argued that KB109 therefore was given for nutritional purposes and was not studied as a COVID-19 treatment.\n\nFor the reasons described below, we conclude that the evidence collected during the inspection shows that KB109 was intended for use as a drug, not as a food, in the two clinical investigations named above.\n\nSection 201(g)(1) of the FD&C Act [21 U.S.C. 321(g)(1)] defines drug as “articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals . . . .” Kaleido studied the efficacy and safety of KB109 to mitigate and treat COVID-19 in subjects who tested positive for COVID-19 as described below:\n\nAs shown by the protocol, a published article supported by Kaleido, and Kaleido’s press releases, the objective of Protocol K031-120 was to compare the safety and efficacy of KB109 in combination with SSC under quarantine protocols set forth by the CDC, with SSC alone in human subjects with mild-to-moderate COVID-19. This study evaluated efficacy endpoints intended to assess KB109 for use in mitigating or treating COVID-19, including change from baseline in, and time to resolution of, overall composite and individual COVID-19-related symptom scores; time to resolution of fever; proportion of subjects with oxygen saturation \u003C95% and \u003C98%; and other endpoints, such as change from baseline in bedrest time, individual measures of quality of life (QOL), proportion of subjects with improvements in patient global impression on COVID-19 condition, proportion of subjects experiencing hospital admissions (all-cause and COVID-19-related), and number of healthcare utilizations.\n\nAs shown by the protocol and a published article supported by Kaleido, the objective of Protocol K032-120 was to compare KB109, in combination with SSC under quarantine protocols set forth by the CDC or local ordinances and practices as advised by a healthcare provider, against SSC alone in human subjects with mild-to-moderate COVID-19. Physiologic effects were assessed by measuring biomarkers of inflammation and antibodies, physiologic responses of health in subjects, QOL, and hospital utilization. This study also assessed the effects of KB109 on the gut microbiome structure and function, and evaluated endpoints related to measures of health, as well as changes in laboratory measures, specific biomarkers, serology, and viral load in the presence and absence of KB109.\n\nFor Protocol K031-120, the endpoints characterized in the protocol as secondary endpoints (for example, time to resolution of individual and composite COVID-19 symptoms, time to resolution of fever, and proportion of subjects hospitalized) clearly assessed the impact of KB109 on clinical manifestations of COVID-19 and were aligned with the recommended efficacy endpoints in published FDA guidances to aid sponsors in developing products to treat patients with COVID-19.4, 5\n\nFor Protocol K032-120, while some endpoints could be considered safety outcomes that might be evaluated only to ensure that treatment with KB109 was not worsening the course of COVID-19, other endpoints (for example, proportion of subjects experiencing hospital admission during the follow-up period, measures of healthcare utilization, and proportion of subjects with oxygen saturation below normal) clearly assessed the use of KB109 in combination with SCC for the treatment or mitigation of COVID-19.\n\nWe note that Kaleido itself described the purpose of KB109 in the clinical investigations conducted under Protocols K031-120 and K032-120 as “treatment of mild to moderate COVID-19” in a communication to FDA.6\n\nTo the extent that Kaleido intended to argue that KB109 was used as a medical food in these clinical investigations, this argument fails for the following reasons:\n\nA product is a medical food if it is “a food . . . intended for the specific dietary management of a disease or condition for which distinctive nutritional requirements, based on recognized scientific principles, are established by medical evaluation.”7 No such distinctive nutritional requirements have been established for COVID-19. Dietary management of a disease is one way to treat or mitigate that disease; therefore, to the extent that a product that does not meet the medical food definition is intended for the dietary management of a disease, it is a drug under section 201(g)(1)(B) of the FD&C Act.\n\nEven if there were distinctive nutritional requirements established for COVID-19, Protocols K031-120 and K032-120 went beyond “dietary management” of COVID-19 to evaluate KB109’s ability to treat COVID-19 by measuring the investigational product’s effects on fever, oxygen saturation, viral load, and other biomarkers of COVID-19 infection, among other things.\n\nFinally, the purported GRAS status of an article for one or more uses in food does not exempt the article from IND requirements when it is studied for use as a drug. In other words, an article may be a drug as used in a clinical trial, even if it is considered a food as used in other contexts. In addition, the instruction for subjects to adhere to CDC guidelines and SSC measures does not preclude investigating KB109 as an add-on therapy in the management of COVID-19 for subjects who are not at high risk for disease worsening or hospitalization.\n\nAs Kaleido noted in its response to the Form FDA 483, whether an investigational article is a drug or a food depends on the intent of the investigation. Based on the study designs of Protocols K031-120 and K032-120, KB109 as used in these clinical investigations was a drug, per 201(g)(1) of the FD&C Act, because KB109 was studied for use in the mitigation and treatment of COVID-19.\n\nThus, before initiating the clinical investigations of KB109 conducted under Protocol K031- 120 and Protocol K032-120, Kaleido was required to submit an IND to FDA and to have an IND in effect under 21 CFR 312.40. FDA’s records indicate that Kaleido failed to submit an IND before conducting these clinical investigations, in which 350 human subjects were randomized at 16 clinical sites for Protocol K031-120, and 49 human subjects were randomized at 7 clinical sites for Protocol K032-120.\n\nIn its response to the Form FDA 483, Kaleido stated that it is developing a procedure for determining the need for an IND (in consultation with FDA) when developing protocols for clinical studies in a disease population where endpoints may be viewed as diagnosing, mitigating, treating, preventing, or curing a disease. Kaleido’s corrective action plan does not provide sufficient details about its new procedure for IND determination. Without these details, we are unable to determine whether Kaleido’s corrective action plan is adequate to prevent similar violations in the future.\n\nThis letter is not intended to be an all-inclusive list of deficiencies with your clinical studies of an investigational drug. It is your responsibility to ensure adherence to each requirement of the law and relevant FDA regulations. You should address any deficiencies and establish procedures to ensure that any ongoing or future studies comply with FDA regulations.\n\nWithin 15 business days of your receipt of this letter, you should notify this office in writing of the actions you have taken to prevent similar violations in the future. Failure to adequately address this matter may lead to regulatory action. If you believe you have complied with the FD&C Act and relevant FDA regulations, please include your reasoning and any supporting information for our consideration.\n\nIf you have any questions, please call Miah Jung, Pharm.D., at 240-402-3728. Alternatively, you may e-mail FDA at CDER-OSI-Communications@fda.hhs.gov. Your written response and any pertinent documentation should be addressed to:\n\nMiah Jung, Pharm.D., M.S., RAC (US)\n\nBranch Chief (Acting)\n\nCompliance Enforcement Branch\n\nDivision of Enforcement and Postmarketing Safety\n\nOffice of Scientific Investigations\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nU.S. Food and Drug Administration\n\nBuilding 51, Room 5219\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993\n\nSincerely yours,\n\n\u002FS\u002F\n\nDavid C. Burrow, Pharm.D., J.D.\n\nDirector\n\nOffice of Scientific Investigations\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nU.S. Food and Drug Administration\n\n_________________\n\n1 Coronavirus Disease 2019 (COVID-19) is the respiratory disease caused by the novel coronavirus called Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).\n\n2 Also, neither of these clinical investigations qualified for any of the exemptions listed at 21 CFR 312.2 from the application of 21 CFR 312.\n\n3 Guidance for Clinical Investigators, Sponsors, and IRBs: Investigational New Drug Applications (INDs) – Determining Whether Human Research Studies Can Be Conducted Without an IND, September 2013.\n\n4 Guidance for industry COVID-19: Developing Drugs and Biological Products for Treatment or Prevention (May 2020; updated February 2021).\n\n5 Guidance for industry Assessing COVID-19-Related Symptoms in Outpatient Adult and Adolescent Subjects in Clinical Trials of Drugs and Biological Products for COVID-19 Prevention or Treatment (September 2020).\n\n6 Pre-IND 151218 Type B Meeting Package for KB109, Kaleido Biosciences, Inc. (July 2, 2020).\n\n7 21 U.S.C. 360ee(b)(3).","Kaleido Biosciences, Inc.","kaleido-biosciences-inc-616026-08262021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fkaleido-biosciences-inc-616026-08262021","2026-10-26T08:09:07.576596+00:00","2021-09-07","616026","Daniel Menichella","2026-08-20T02:37:45.127+00:00","21-HFD-45-08-01","2021-08-26",{"id":167,"raw":168,"subject":41,"body_html":173,"body_text":174,"firm_name":175,"letter_id":176,"created_at":177,"fei_number":20,"letter_url":178,"updated_at":179,"action_type":23,"case_status":49,"posted_date":180,"marcs_cms_no":181,"product_type":52,"closeout_date":20,"issuing_office":172,"recipient_name":182,"body_fetched_at":183,"delivery_method":122,"recipient_title":20,"reference_number":184,"action_taken_date":185,"medical_device_id":20,"response_letter_date":20},2429,[169,170,171,172,40,13,13,13],"\u003Ctime datetime=\"2022-09-20T13:20:00Z\">09\u002F20\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-08-23T04:00:00Z\">08\u002F23\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbiolab-sciences-inc-621465-08232022\">BioLab Sciences, Inc.\u003C\u002Fa>","Office of Biological Products Operations – Division 2","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>OBPO 621465\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Robert D. Maguire\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>BioLab Sciences, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>13825 N. Northsight Blvd., Suite 101\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Scottsdale\u003C\u002Fspan>, \u003Cspan>AZ\u003C\u002Fspan> \u003Cspan>85260\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Biological Products Operations – Division 2\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>August 23, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Maguire:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm, BioLab Sciences, Inc. (hereinafter, “BioLab Sciences”), located at 7662 E. Gray Rd., Suite 107, Scottsdale, AZ 85260, conducted between August 23, 2021, and September 3, 2021, the United States Food and Drug Administration (FDA) documented that you manufacture products derived from human amniotic fluid, specifically, Fluid GF™, Restore GF™, Fluid Flow™, Amnio Restore™,&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>, and Stimuleyes™, for allogeneic use, and an epidermal skin tissue product, MyOwnSkin™ and MySkinRestore™, for autologous use (collectively, “your products”).\u003Csup>\u003Cem>\u003Cstrong>1,2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> You have distributed your products to third-party distributors, some under private label, as well as directly to healthcare professionals throughout the United States. Your amniotic fluid products are intended for injection and are purported to be sterile.\u003C\u002Fp>\n\n\u003Cp>Information and records gathered prior to and during the inspection, including information on your website, www.biolabsciences.com, reflect your products are intended to treat various diseases or conditions. Additionally, information collected indicates your products fit within the definition of a biological product in the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)]. Therefore, your products are drugs as defined in section 201(g) of the Federal Food, Drug, and Cosmetic Act (the FD&amp;C Act) [21 U.S.C. 321(g)] and biological products as defined in section 351(i) of the PHS Act.\u003C\u002Fp>\n\n\u003Cp>MyOwnSkin™ and MySkinRestore™ are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act [42 U.S.C. 264]. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act, and are subject to additional regulation, including appropriate premarket review. 21 CFR 1271.20.\u003C\u002Fp>\n\n\u003Cp>Based on a review of materials described above, BioLab Sciences does not qualify for any exception in 21 CFR 1271.15, and MyOwnSkin™ and MySkinRestore™ fail to meet all the criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\n\n\u003Cp>Specifically, MyOwnSkin™ and MySkinRestore™ fail to meet the criterion set forth in 21 CFR 1271.10(a)(1) that they not be more than minimally manipulated as such term is defined for structural tissue in 21 CFR 1271.3(f)(1). Because your processing alters the original relevant characteristics of the skin related to its utility for reconstruction, repair, or replacement, MyOwnSkin™ and MySkinRestore™ are more than minimally manipulated.\u003C\u002Fp>\n\n\u003Cp>MyOwnSkin™ and MySkinRestore™ also fail to meet other criteria set forth in 21 CFR 1271.10(a). An HCT\u002FP meets the criterion in 21 CFR 1271.10(a)(2) if the HCT\u002FP is “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent.” MyOwnSkin™ and MySkinRestore™ are not intended to perform the same basic function or functions of skin in the recipient as in the donor, such as serving as a protective covering. Rather, these products are intended as advanced wound care therapies, including to regenerate skin in various wounds. Such use is not homologous use as defined in 21 CFR 1271.3(c).\u003C\u002Fp>\n\n\u003Cp>An HCT\u002FP meets the criterion in 21 CFR 1271.10(a)(3) if “the manufacture of the HCT\u002FP does not involve the combination with another article, except for water, crystalloids, or a sterilizing, preserving, or storage agent, provided that the addition of water, crystalloids, or the sterilizing, preserving, or storage agent does not raise new clinical safety concerns with respect to the HCT\u002FP.” Based on the processing and product information available for MyOwnSkin™ and MySkinRestore™, skin cells from a patient’s skin are&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> prior to shipment and implantation in the same individual. Therefore, this criterion is also not met.\u003C\u002Fp>\n\n\u003Cp>Because Biolab Sciences does not qualify for any exception in 21 CFR 1271.15, and because MyOwnSkin™ and MySkinRestore™ do not meet all the criteria in 21 CFR 1271.10(a), these products are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR Part 1271. MyOwnSkin™ and MySkinRestore™ appear to be combination products and would be regulated under the statutory authorities applicable to drugs as defined in section 201(g) of the FD&amp;C Act [21 U.S.C. 321(g)] and biological products as defined in section 351(i) of the PHS Act [42 U.S.C. 262(i)].\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Please be advised that the definition of HCT\u002FPs in 21 CFR 1271.3(d) excludes secreted or extracted human products. Accordingly, secreted bodily fluids, such as amniotic fluid, are generally not considered HCT\u002FPs subject to regulation under 21 CFR Part 1271. Amniotic fluid intended to treat diseases or conditions in humans is generally regulated as a drug under the FD&amp;C Act and a biological product under the PHS Act and requires premarket review and approval. As such, your products derived from amniotic fluid, Fluid GF™, Restore GF™, Fluid Flow™, Amnio Retore™, Stimuleyes™, and&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>, are also regulated as drugs and biological products under section 351 of the PHS Act and the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>In order to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312]. None of your products are the subject of an approved biologics license application (BLA), nor is there an IND in effect for any of them. Based on this information, we have determined that your actions have violated the FD&amp;C Act and the PHS Act.\u003C\u002Fp>\n\n\u003Cp>Additionally, during the inspection, FDA investigators documented evidence of significant deviations from current good manufacturing practice (CGMP) requirements, including deviations from section 501(a)(2)(B) of the FD&amp;C Act and 21 CFR Parts 210 and 211.\u003C\u002Fp>\n\n\u003Cp>At the close of the inspection, the FDA investigators issued a Form FDA-483, List of Inspectional Observations, which described a number of significant CGMP deviations applicable to your products. FDA identified additional significant deviations upon further review of the information collected during the inspection, as described below. Additionally, we have received a safety concern about one of your products.\u003C\u002Fp>\n\n\u003Cp>Your CGMP deficiencies, involving over \u003Cstrong>(b)(4)\u003C\u002Fstrong> units of products manufactured between March 2019 and the present, include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure to establish appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile, including procedures for validation of all aseptic and sterilization processes [21 CFR 211.113(b)].\u003C\u002Fstrong> For example:\u003C\u002Fp>\n\n\u003Cp>a. You failed to validate the aseptic processes used to manufacture over&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> units of Fluid Flow™, Amnio Restore™,\u003Cstrong>(b)(4)\u003C\u002Fstrong>, Stimuleyes™, Fluid GF™, and Restore GF™ (i.e., by performing media fill simulations) since your manufacturing operations began in March 2019. Based on your product labeling, these products purport to be sterile and are expected to be sterile.\u003C\u002Fp>\n\n\u003Cp>b. Your firm failed to validate the sterilization process for Fluid GF™ and Restore GF™. You have manufactured and distributed over \u003Cstrong>(b)(4)\u003C\u002Fstrong> units of these products since June 22, 2021.\u003C\u002Fp>\n\n\u003Cp>c. Your Fluid Flow™ \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization validation, entitled “\u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>Sterilization Validation Report,” RST-1052, dated May 20, 2019, is inadequate. For example:\u003C\u002Fp>\n\n\u003Cp>&nbsp; i. You have had failures during your dose verification audit where it was noted that the established dose to achieve sterility was not adequate and for which you made no changes to your process.\u003C\u002Fp>\n\n\u003Cp>&nbsp; ii. You did not assess the impact of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization on the integrity of the amniotic fluid product’s container-closure system to assure that sterility is maintained.\u003C\u002Fp>\n\n\u003Cp>d. The frequency of monitoring conducted in the critical aseptic areas is insufficient to detect problems and demonstrate control. For example:\u003C\u002Fp>\n\n\u003Cp>&nbsp; i. Surface samples for microbiological monitoring are not collected in the Biological Safety Cabinets (BSCs) directly after processing of your amniotic fluid products. Environmental monitoring should be conducted directly after processing, before cleaning is performed, in order to monitor processing conditions and demonstrate control of the critical area during aseptic processing.\u003C\u002Fp>\n\n\u003Cp>&nbsp; ii. Personnel monitoring is required only every \u003Cstrong>(b)(4)\u003C\u002Fstrong> for personnel who process your amniotic fluid products.\u003C\u002Fp>\n\n\u003Cp>e. In accordance with your cleanroom gowning procedure, personnel performing aseptic processing wear non-sterile personal protective equipment (PPE), such as hair covers, beard covers, and shoe covers, that does not adequately protect against microbiological contamination of your products.\u003C\u002Fp>\n\n\u003Cp>f. During the inspection, FDA investigators observed personnel practices that do not adequately protect against microbiological contamination of your products. For example, operators were observed exiting and entering the cleanroom quickly and frequently during manufacturing operations. This practice potentially disturbs the airflow in the cleanroom environment and could introduce contaminants into the cleanroom.\u003C\u002Fp>\n\n\u003Cp>g. Your written environmental monitoring procedure now describes that \u003Cstrong>(b)(4)\u003C\u002Fstrong> colony forming units (CFUs) is an acceptable result on environmental monitoring plates intended to detect the presence of microorganisms in the critical processing area. This allowance for such high numbers of microorganisms could contribute to product contamination and pose a potentially significant safety concern. For additional information, we recommend that you review FDA Guidance for Industry, Sterile Drug Products Produced by Aseptic Processing – Current Good Manufacturing Practice, available at \u003Ca>www.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidances\u002Fucm070342.pdf\u003C\u002Fa>. FDA’s guidance documents do not establish legal requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Failure to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality, and purity [21 CFR 211.160(b)].\u003C\u002Fstrong> For example, your firm has not established appropriate specifications and test procedures to assure that your amniotic fluid products conform to appropriate standards of identity, strength, quality, and purity. Your finished product testing is limited to a visual examination.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Failure to establish and follow written procedures for cleaning and maintenance of equipment used in the manufacture, processing, packing, or holding of a drug product [ 21 CFR 211.67(b)].\u003C\u002Fstrong> For example:\u003C\u002Fp>\n\n\u003Cp>a. Your firm failed to validate the cleaning process for your BSCs.\u003Cbr>\n\u003Cbr>\nb. Your firm has not adequately established and followed written procedures for cleaning the \u003Cstrong>(b)(4)\u003C\u002Fstrong> BSCs used to manufacture your products. For example, your written procedure for cleaning does not include the \u003Cstrong>(b)(4)\u003C\u002Fstrong> when \u003Cstrong>(b)(4)\u003C\u002Fstrong> is used to clean the BSCs during \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleanings.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Failure to establish and follow written procedures describing in sufficient detail the methods and materials used for sanitation [21 CFR 211.56(b)]. \u003C\u002Fstrong>For example:\u003C\u002Fp>\n\n\u003Cp>a. Your firm failed to validate the cleaning process for your cleanrooms.\u003C\u002Fp>\n\n\u003Cp>b. Your firm has not adequately established and followed written procedures for cleaning the cleanrooms used to manufacture your products. For example:\u003C\u002Fp>\n\n\u003Cp>&nbsp; i. In accordance with your cleanroom cleaning procedure, a \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>cleaning of all contact surfaces in the cleanrooms is required at the&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> processing operations. However, a review of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning records revealed that this required cleaning is not always performed, and a justification is not always provided.\u003C\u002Fp>\n\n\u003Cp>&nbsp; ii. You failed to ensure sufficient use of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, a sporicidal agent, in your disinfection program, as required by your cleanroom cleaning procedure. For example, your firm identified \u003Cem>Bacillus\u003C\u002Fem>, species, a spore-forming organism, on your cleanroom floors. You noted that \u003Cstrong>(b)(4)\u003C\u002Fstrong> was not used to disinfect the area because the floors were constructed of materials not normally used in cleanrooms.\u003C\u002Fp>\n\n\u003Cp>&nbsp; iii. Your written procedure for cleanroom cleaning does not include the&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> when \u003Cstrong>(b)(4)\u003C\u002Fstrong> is used during \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleanings.\u003C\u002Fp>\n\n\u003Cp>&nbsp; iv. The cleaning records do not include dilutions or contact times. During the inspection, no data or rationale for the cleaning agents used or their rotation was provided.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>5. Your aseptic processing areas are deficiently designed in that the floors are not smooth, hard surfaces that are easily cleanable in order to prevent contamination [21 CFR 211.42(c)(10)(i)].\u003C\u002Fstrong> For example, your cleanrooms floors have seams and gaps rendering them difficult to clean and disinfect.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>6. Failure to thoroughly investigate any unexplained discrepancy or the failure of a batch or any of its components to meet any of its&nbsp;\u003C\u002Fstrong>\u003Cstrong>specifications whether or not the batch has been already distributed [21 CFR 211.192].\u003C\u002Fstrong> For example, between October 30, 2020, and July 30, 2021, you failed to investigate approximately 90% of your excursions for microbiological monitoring of the cleanroom environment, including two excursions in the critical processing area (i.e., inside your BSCs). While you identified the contaminating organisms, you did not thoroughly investigate the excursions to determine the root cause, product impact, and corrective and preventive actions. Examples of microorganisms identified in your cleanroom include \u003Cem>Bacillus\u003C\u002Fem> species non-anthracis, \u003Cem>Fictibacillus\u003C\u002Fem> species, \u003Cem>Bacillus pumilus\u003C\u002Fem>, Gram Positive Cocci, fungi, and \u003Cem>Bacillus megaterium\u003C\u002Fem>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>7. Failure to ensure that each lot of components, drug product containers, and closures are withheld from use until the lot has been sampled, tested, or examined, as appropriate, and released for use by the quality control unit [21 CFR 211.84].\u003C\u002Fstrong> For example:\u003C\u002Fp>\n\n\u003Cp>a. Your firm used \u003Cstrong>(b)(4)\u003C\u002Fstrong> to manufacture approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches of MyOwnSkin™ and MySkinRestore™ between June 27, 2019, and September 24, 2021, even though such components had not been examined and released for use by the quality control unit. These components are labeled for research use only.\u003C\u002Fp>\n\n\u003Cp>b. Your firm used \u003Cstrong>(b)(4)\u003C\u002Fstrong>, to manufacture MyOwnSkin™ and MySkinRestore™, even though such components had not been examined and released for use by the quality control unit. The labeling of those components advises against their use in “Human or Animal Drugs.”\u003C\u002Fp>\n\n\u003Cp>c. Your firm lacks evidence, such as testing, to demonstrate that these components meet all specifications of identity, strength, quality, and purity.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>8. Failure to establish written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)].\u003C\u002Fstrong> Specifically, your firm has not validated the manufacturing processes for Fluid GF™, Restore GF™, Fluid Flow™, Amnio Restore™, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Stimuleyes™, MyOwnSkin™, and MySkinRestore™.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>9. Failure to establish and follow a written testing program designed to assess the stability characteristics of drug products and to use the results of such stability testing to determine appropriate storage conditions and expiration dates [21 CFR 211.166(a)].\u003C\u002Fstrong> Specifically, your firm has assigned a twelve-month expiration date to your amniotic fluid products and a 24-hour expiration date to your skin products without supporting data from stability testing.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your written responses, dated September 27, 2021, November 30, 2021, February 14, 2022, March 26, 2022, May 26, 2022, and July 26, 2022, to the inspectional observations on the Form FDA-483, and we have determined that they are inadequate to address our concerns.\u003C\u002Fp>\n\n\u003Cp>We acknowledge your commitment to voluntarily cease the manufacture and distribution of MyOwnSkin™ and MySkinRestore™ until an IND is in effect for such products.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> You also explain that you currently market amniotic membrane products, Membrane Wrap™ and Membrane Restore™, and amniotic fluid products, Fluid GF™ and Restore GF™, and commit that all other tissue products marketed in the past under additional brand names have been discontinued. Please note that amniotic fluid products are not considered tissue products. We acknowledge that you report having discontinued manufacturing \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Stimuleyes™, Fluid Flow™, and Amnio Restore™.\u003C\u002Fp>\n\n\u003Cp>Your responses, however, do not adequately address your failure to have an IND in effect for your amniotic fluid products and your lack of an approved BLA to lawfully market those products. As noted above, to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such a product may be distributed for clinical use in humans only if the sponsor has an IND in effect, as specified by FDA regulations, that covers such clinical use [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312].\u003C\u002Fp>\n\n\u003Cp>Your response also does not adequately address any inventory of Fluid GF™, Fluid Flow™, Restore GF™, and Amnio Restore™ at your facility. In response to this letter, provide your specific plans for the disposition of all of these products. Please also explain in detail your intention to use your inventory of Fluid Flow™ and Amnio Restore™, currently in quarantine, for “potential research use.”\u003C\u002Fp>\n\n\u003Cp>We note that you have previously marketed Amnio Breathe™, a nebulizer bundle containing Fluid Flow™. In response to this letter, please also inform FDA whether you are currently marketing this product or intend to in the future.\u003C\u002Fp>\n\n\u003Cp>Finally, we note that in your responses you discuss updates to your procedures in an attempt to comply with CGMP requirements. We have reviewed those updates and listed your CGMP deficiencies above. We are not providing further input on your updates to procedures in this letter.\u003C\u002Fp>\n\n\u003Cp>Neither this letter nor the observations noted on the Form FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies. It is your responsibility to ensure full compliance with the FD&amp;C Act, PHS Act, and all applicable regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions include seizure and\u002For injunction.\u003C\u002Fp>\n\n\u003Cp>For further information about IND requirements, please contact the Center for Biologics Evaluation and Research (CBER), Division of Regulatory Project Management, Office of Tissues and Advanced Therapies, at (240) 402-8190, or OTATRPMS@fda.hhs.gov. Please include a copy of this letter with your initial submission to CBER.\u003C\u002Fp>\n\n\u003Cp>We request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to correct the noted violations and prevent their recurrence. Include any documentation necessary to show that matters have been addressed. If you do not believe your products are in violation of the FD&amp;C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot address these matters completely within fifteen (15) working days, please explain the reason for your delay and the time frame for completion.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to the following address: Amy Graf, Compliance Officer, U.S. Food and Drug Administration, Office of Biological Products Operations – Division 2, 300 River Place Dr. – Suite 5900, Detroit, MI 48207 or emailed to Amy.Graf@fda.hhs.gov. If you have any questions, please contact Ms. Graf at (313) 393-2034 or via e-mail.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Karlton T. Watson\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Biological Products Operations – Division 2\u003C\u002Fp>\n\n\u003Cp>Cc: Robert D. Maguire\u003Cbr>\nPresident and Chief Executive Officer\u003Cbr>\nBioLab Sciences, Inc.\u003Cbr>\n7662 East Gray Road, Suite 107\u003Cbr>\nScottsdale, AZ 85260\u003C\u002Fp>\n\n\u003Cp>_________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> This letter only pertains to Fluid GF™, Restore GF™, Fluid Flow™, Amnio Restore™,&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>, Stimuleyes™, MyOwnSkin™, and MySkinRestore™. You also manufacture products derived from amniotic membrane, including Membrane Wrap™, Membrane Restore™, and Vision Sphere™. Please be advised that Membrane Wrap™ does not appear to meet the homologous use only criterion at 21 CFR 1271.10(a)(2). You describe this product as a “human tissue allograft derived from amniotic membrane that provides structural tissue for use as a wound and protectant covering.” Use of Membrane Wrap™ as a wound covering would be considered a homologous use. However, you also market this product, for example, to reduce pain and scarring, adhere wounds, heal, and as “anti-bacterial” and for “immune privileged[] and neovascularization.” Such uses are considered nonhomologous uses for amniotic membrane. Membrane Wrap™ must meet all the criteria at 21 CFR 1271.10(a), including the homologous use criterion at 21 CFR 1271.10(a)(2), to be regulated solely under section 361 of the Public Health Service Act and the regulations in 21 CFR Part 1271. This letter does not otherwise address your amniotic membrane products.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Some of your products are the same products marketed under different brand names. For example, you represented to FDA that \u003Cstrong>(b)(4)\u003C\u002Fstrong> is the same product as Stimuleyes™. Likewise, MyOwnSkin™ and MySkinRestore™ are the same product marketed under different brand names.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> As combination products, MyOwnSkin™ and MySkinRestore™ would be appropriately assigned to the Center for Biologics Evaluation and Research (CBER) based on the combination products’ primary mode of action. \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4 \u003C\u002Fstrong>\u003C\u002Fem>We note that you had been informed by FDA prior to FDA’s inspection that MyOwnSkin™ appeared to be regulated as a combination product. Nevertheless, you continued to manufacture and distribute this product without premarketing approval until September 24, 2021.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nReference #:\n\nOBPO 621465\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nRobert D. Maguire\n\nRecipient Title\n\nPresident and Chief Executive Officer\n\nBioLab Sciences, Inc.\n\n13825 N. Northsight Blvd., Suite 101\n\nScottsdale, AZ 85260\n\nUnited States\n\nIssuing Office:\n\nOffice of Biological Products Operations – Division 2\n\nUnited States\n\nWARNING LETTER\n\nAugust 23, 2022\n\nDear Mr. Maguire:\n\nDuring an inspection of your firm, BioLab Sciences, Inc. (hereinafter, “BioLab Sciences”), located at 7662 E. Gray Rd., Suite 107, Scottsdale, AZ 85260, conducted between August 23, 2021, and September 3, 2021, the United States Food and Drug Administration (FDA) documented that you manufacture products derived from human amniotic fluid, specifically, Fluid GF™, Restore GF™, Fluid Flow™, Amnio Restore™, (b)(4), and Stimuleyes™, for allogeneic use, and an epidermal skin tissue product, MyOwnSkin™ and MySkinRestore™, for autologous use (collectively, “your products”).1,2 You have distributed your products to third-party distributors, some under private label, as well as directly to healthcare professionals throughout the United States. Your amniotic fluid products are intended for injection and are purported to be sterile.\n\nInformation and records gathered prior to and during the inspection, including information on your website, www.biolabsciences.com, reflect your products are intended to treat various diseases or conditions. Additionally, information collected indicates your products fit within the definition of a biological product in the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)]. Therefore, your products are drugs as defined in section 201(g) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) [21 U.S.C. 321(g)] and biological products as defined in section 351(i) of the PHS Act.\n\nMyOwnSkin™ and MySkinRestore™ are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act [42 U.S.C. 264]. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act, and are subject to additional regulation, including appropriate premarket review. 21 CFR 1271.20.\n\nBased on a review of materials described above, BioLab Sciences does not qualify for any exception in 21 CFR 1271.15, and MyOwnSkin™ and MySkinRestore™ fail to meet all the criteria in 21 CFR 1271.10(a).\n\nSpecifically, MyOwnSkin™ and MySkinRestore™ fail to meet the criterion set forth in 21 CFR 1271.10(a)(1) that they not be more than minimally manipulated as such term is defined for structural tissue in 21 CFR 1271.3(f)(1). Because your processing alters the original relevant characteristics of the skin related to its utility for reconstruction, repair, or replacement, MyOwnSkin™ and MySkinRestore™ are more than minimally manipulated.\n\nMyOwnSkin™ and MySkinRestore™ also fail to meet other criteria set forth in 21 CFR 1271.10(a). An HCT\u002FP meets the criterion in 21 CFR 1271.10(a)(2) if the HCT\u002FP is “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent.” MyOwnSkin™ and MySkinRestore™ are not intended to perform the same basic function or functions of skin in the recipient as in the donor, such as serving as a protective covering. Rather, these products are intended as advanced wound care therapies, including to regenerate skin in various wounds. Such use is not homologous use as defined in 21 CFR 1271.3(c).\n\nAn HCT\u002FP meets the criterion in 21 CFR 1271.10(a)(3) if “the manufacture of the HCT\u002FP does not involve the combination with another article, except for water, crystalloids, or a sterilizing, preserving, or storage agent, provided that the addition of water, crystalloids, or the sterilizing, preserving, or storage agent does not raise new clinical safety concerns with respect to the HCT\u002FP.” Based on the processing and product information available for MyOwnSkin™ and MySkinRestore™, skin cells from a patient’s skin are (b)(4) prior to shipment and implantation in the same individual. Therefore, this criterion is also not met.\n\nBecause Biolab Sciences does not qualify for any exception in 21 CFR 1271.15, and because MyOwnSkin™ and MySkinRestore™ do not meet all the criteria in 21 CFR 1271.10(a), these products are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR Part 1271. MyOwnSkin™ and MySkinRestore™ appear to be combination products and would be regulated under the statutory authorities applicable to drugs as defined in section 201(g) of the FD&C Act [21 U.S.C. 321(g)] and biological products as defined in section 351(i) of the PHS Act [42 U.S.C. 262(i)].3\n\nPlease be advised that the definition of HCT\u002FPs in 21 CFR 1271.3(d) excludes secreted or extracted human products. Accordingly, secreted bodily fluids, such as amniotic fluid, are generally not considered HCT\u002FPs subject to regulation under 21 CFR Part 1271. Amniotic fluid intended to treat diseases or conditions in humans is generally regulated as a drug under the FD&C Act and a biological product under the PHS Act and requires premarket review and approval. As such, your products derived from amniotic fluid, Fluid GF™, Restore GF™, Fluid Flow™, Amnio Retore™, Stimuleyes™, and (b)(4), are also regulated as drugs and biological products under section 351 of the PHS Act and the FD&C Act.\n\nIn order to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312]. None of your products are the subject of an approved biologics license application (BLA), nor is there an IND in effect for any of them. Based on this information, we have determined that your actions have violated the FD&C Act and the PHS Act.\n\nAdditionally, during the inspection, FDA investigators documented evidence of significant deviations from current good manufacturing practice (CGMP) requirements, including deviations from section 501(a)(2)(B) of the FD&C Act and 21 CFR Parts 210 and 211.\n\nAt the close of the inspection, the FDA investigators issued a Form FDA-483, List of Inspectional Observations, which described a number of significant CGMP deviations applicable to your products. FDA identified additional significant deviations upon further review of the information collected during the inspection, as described below. Additionally, we have received a safety concern about one of your products.\n\nYour CGMP deficiencies, involving over (b)(4) units of products manufactured between March 2019 and the present, include, but are not limited to, the following:\n\n1. Failure to establish appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile, including procedures for validation of all aseptic and sterilization processes [21 CFR 211.113(b)]. For example:\n\na. You failed to validate the aseptic processes used to manufacture over (b)(4) units of Fluid Flow™, Amnio Restore™,(b)(4), Stimuleyes™, Fluid GF™, and Restore GF™ (i.e., by performing media fill simulations) since your manufacturing operations began in March 2019. Based on your product labeling, these products purport to be sterile and are expected to be sterile.\n\nb. Your firm failed to validate the sterilization process for Fluid GF™ and Restore GF™. You have manufactured and distributed over (b)(4) units of these products since June 22, 2021.\n\nc. Your Fluid Flow™ (b)(4) sterilization validation, entitled “(b)(4) Sterilization Validation Report,” RST-1052, dated May 20, 2019, is inadequate. For example:\n\ni. You have had failures during your dose verification audit where it was noted that the established dose to achieve sterility was not adequate and for which you made no changes to your process.\n\nii. You did not assess the impact of the (b)(4) sterilization on the integrity of the amniotic fluid product’s container-closure system to assure that sterility is maintained.\n\nd. The frequency of monitoring conducted in the critical aseptic areas is insufficient to detect problems and demonstrate control. For example:\n\ni. Surface samples for microbiological monitoring are not collected in the Biological Safety Cabinets (BSCs) directly after processing of your amniotic fluid products. Environmental monitoring should be conducted directly after processing, before cleaning is performed, in order to monitor processing conditions and demonstrate control of the critical area during aseptic processing.\n\nii. Personnel monitoring is required only every (b)(4) for personnel who process your amniotic fluid products.\n\ne. In accordance with your cleanroom gowning procedure, personnel performing aseptic processing wear non-sterile personal protective equipment (PPE), such as hair covers, beard covers, and shoe covers, that does not adequately protect against microbiological contamination of your products.\n\nf. During the inspection, FDA investigators observed personnel practices that do not adequately protect against microbiological contamination of your products. For example, operators were observed exiting and entering the cleanroom quickly and frequently during manufacturing operations. This practice potentially disturbs the airflow in the cleanroom environment and could introduce contaminants into the cleanroom.\n\ng. Your written environmental monitoring procedure now describes that (b)(4) colony forming units (CFUs) is an acceptable result on environmental monitoring plates intended to detect the presence of microorganisms in the critical processing area. This allowance for such high numbers of microorganisms could contribute to product contamination and pose a potentially significant safety concern. For additional information, we recommend that you review FDA Guidance for Industry, Sterile Drug Products Produced by Aseptic Processing – Current Good Manufacturing Practice, available at www.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidances\u002Fucm070342.pdf. FDA’s guidance documents do not establish legal requirements.\n\n2. Failure to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality, and purity [21 CFR 211.160(b)]. For example, your firm has not established appropriate specifications and test procedures to assure that your amniotic fluid products conform to appropriate standards of identity, strength, quality, and purity. Your finished product testing is limited to a visual examination.\n\n3. Failure to establish and follow written procedures for cleaning and maintenance of equipment used in the manufacture, processing, packing, or holding of a drug product [ 21 CFR 211.67(b)]. For example:\n\na. Your firm failed to validate the cleaning process for your BSCs.\n\nb. Your firm has not adequately established and followed written procedures for cleaning the (b)(4) BSCs used to manufacture your products. For example, your written procedure for cleaning does not include the (b)(4) when (b)(4) is used to clean the BSCs during (b)(4) cleanings.\n\n4. Failure to establish and follow written procedures describing in sufficient detail the methods and materials used for sanitation [21 CFR 211.56(b)]. For example:\n\na. Your firm failed to validate the cleaning process for your cleanrooms.\n\nb. Your firm has not adequately established and followed written procedures for cleaning the cleanrooms used to manufacture your products. For example:\n\ni. In accordance with your cleanroom cleaning procedure, a (b)(4) cleaning of all contact surfaces in the cleanrooms is required at the (b)(4) processing operations. However, a review of your (b)(4) cleaning records revealed that this required cleaning is not always performed, and a justification is not always provided.\n\nii. You failed to ensure sufficient use of (b)(4), a sporicidal agent, in your disinfection program, as required by your cleanroom cleaning procedure. For example, your firm identified Bacillus, species, a spore-forming organism, on your cleanroom floors. You noted that (b)(4) was not used to disinfect the area because the floors were constructed of materials not normally used in cleanrooms.\n\niii. Your written procedure for cleanroom cleaning does not include the (b)(4) when (b)(4) is used during (b)(4) cleanings.\n\niv. The cleaning records do not include dilutions or contact times. During the inspection, no data or rationale for the cleaning agents used or their rotation was provided.\n\n5. Your aseptic processing areas are deficiently designed in that the floors are not smooth, hard surfaces that are easily cleanable in order to prevent contamination [21 CFR 211.42(c)(10)(i)]. For example, your cleanrooms floors have seams and gaps rendering them difficult to clean and disinfect.\n\n6. Failure to thoroughly investigate any unexplained discrepancy or the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed [21 CFR 211.192]. For example, between October 30, 2020, and July 30, 2021, you failed to investigate approximately 90% of your excursions for microbiological monitoring of the cleanroom environment, including two excursions in the critical processing area (i.e., inside your BSCs). While you identified the contaminating organisms, you did not thoroughly investigate the excursions to determine the root cause, product impact, and corrective and preventive actions. Examples of microorganisms identified in your cleanroom include Bacillus species non-anthracis, Fictibacillus species, Bacillus pumilus, Gram Positive Cocci, fungi, and Bacillus megaterium.\n\n7. Failure to ensure that each lot of components, drug product containers, and closures are withheld from use until the lot has been sampled, tested, or examined, as appropriate, and released for use by the quality control unit [21 CFR 211.84]. For example:\n\na. Your firm used (b)(4) to manufacture approximately (b)(4) batches of MyOwnSkin™ and MySkinRestore™ between June 27, 2019, and September 24, 2021, even though such components had not been examined and released for use by the quality control unit. These components are labeled for research use only.\n\nb. Your firm used (b)(4), to manufacture MyOwnSkin™ and MySkinRestore™, even though such components had not been examined and released for use by the quality control unit. The labeling of those components advises against their use in “Human or Animal Drugs.”\n\nc. Your firm lacks evidence, such as testing, to demonstrate that these components meet all specifications of identity, strength, quality, and purity.\n\n8. Failure to establish written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)]. Specifically, your firm has not validated the manufacturing processes for Fluid GF™, Restore GF™, Fluid Flow™, Amnio Restore™, (b)(4), Stimuleyes™, MyOwnSkin™, and MySkinRestore™.\n\n9. Failure to establish and follow a written testing program designed to assess the stability characteristics of drug products and to use the results of such stability testing to determine appropriate storage conditions and expiration dates [21 CFR 211.166(a)]. Specifically, your firm has assigned a twelve-month expiration date to your amniotic fluid products and a 24-hour expiration date to your skin products without supporting data from stability testing.\n\nWe have reviewed your written responses, dated September 27, 2021, November 30, 2021, February 14, 2022, March 26, 2022, May 26, 2022, and July 26, 2022, to the inspectional observations on the Form FDA-483, and we have determined that they are inadequate to address our concerns.\n\nWe acknowledge your commitment to voluntarily cease the manufacture and distribution of MyOwnSkin™ and MySkinRestore™ until an IND is in effect for such products.4 You also explain that you currently market amniotic membrane products, Membrane Wrap™ and Membrane Restore™, and amniotic fluid products, Fluid GF™ and Restore GF™, and commit that all other tissue products marketed in the past under additional brand names have been discontinued. Please note that amniotic fluid products are not considered tissue products. We acknowledge that you report having discontinued manufacturing (b)(4), Stimuleyes™, Fluid Flow™, and Amnio Restore™.\n\nYour responses, however, do not adequately address your failure to have an IND in effect for your amniotic fluid products and your lack of an approved BLA to lawfully market those products. As noted above, to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such a product may be distributed for clinical use in humans only if the sponsor has an IND in effect, as specified by FDA regulations, that covers such clinical use [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312].\n\nYour response also does not adequately address any inventory of Fluid GF™, Fluid Flow™, Restore GF™, and Amnio Restore™ at your facility. In response to this letter, provide your specific plans for the disposition of all of these products. Please also explain in detail your intention to use your inventory of Fluid Flow™ and Amnio Restore™, currently in quarantine, for “potential research use.”\n\nWe note that you have previously marketed Amnio Breathe™, a nebulizer bundle containing Fluid Flow™. In response to this letter, please also inform FDA whether you are currently marketing this product or intend to in the future.\n\nFinally, we note that in your responses you discuss updates to your procedures in an attempt to comply with CGMP requirements. We have reviewed those updates and listed your CGMP deficiencies above. We are not providing further input on your updates to procedures in this letter.\n\nNeither this letter nor the observations noted on the Form FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies. It is your responsibility to ensure full compliance with the FD&C Act, PHS Act, and all applicable regulations.\n\nThis letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions include seizure and\u002For injunction.\n\nFor further information about IND requirements, please contact the Center for Biologics Evaluation and Research (CBER), Division of Regulatory Project Management, Office of Tissues and Advanced Therapies, at (240) 402-8190, or OTATRPMS@fda.hhs.gov. Please include a copy of this letter with your initial submission to CBER.\n\nWe request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to correct the noted violations and prevent their recurrence. Include any documentation necessary to show that matters have been addressed. If you do not believe your products are in violation of the FD&C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot address these matters completely within fifteen (15) working days, please explain the reason for your delay and the time frame for completion.\n\nYour response should be sent to the following address: Amy Graf, Compliance Officer, U.S. Food and Drug Administration, Office of Biological Products Operations – Division 2, 300 River Place Dr. – Suite 5900, Detroit, MI 48207 or emailed to Amy.Graf@fda.hhs.gov. If you have any questions, please contact Ms. Graf at (313) 393-2034 or via e-mail.\n\nSincerely,\n\n\u002FS\u002F\n\nKarlton T. Watson\n\nProgram Division Director\n\nOffice of Biological Products Operations – Division 2\n\nCc: Robert D. Maguire\n\nPresident and Chief Executive Officer\n\nBioLab Sciences, Inc.\n\n7662 East Gray Road, Suite 107\n\nScottsdale, AZ 85260\n\n_________________________\n\n1 This letter only pertains to Fluid GF™, Restore GF™, Fluid Flow™, Amnio Restore™, (b)(4), Stimuleyes™, MyOwnSkin™, and MySkinRestore™. You also manufacture products derived from amniotic membrane, including Membrane Wrap™, Membrane Restore™, and Vision Sphere™. Please be advised that Membrane Wrap™ does not appear to meet the homologous use only criterion at 21 CFR 1271.10(a)(2). You describe this product as a “human tissue allograft derived from amniotic membrane that provides structural tissue for use as a wound and protectant covering.” Use of Membrane Wrap™ as a wound covering would be considered a homologous use. However, you also market this product, for example, to reduce pain and scarring, adhere wounds, heal, and as “anti-bacterial” and for “immune privileged[] and neovascularization.” Such uses are considered nonhomologous uses for amniotic membrane. Membrane Wrap™ must meet all the criteria at 21 CFR 1271.10(a), including the homologous use criterion at 21 CFR 1271.10(a)(2), to be regulated solely under section 361 of the Public Health Service Act and the regulations in 21 CFR Part 1271. This letter does not otherwise address your amniotic membrane products.\n\n2 Some of your products are the same products marketed under different brand names. For example, you represented to FDA that (b)(4) is the same product as Stimuleyes™. Likewise, MyOwnSkin™ and MySkinRestore™ are the same product marketed under different brand names.\n\n3 As combination products, MyOwnSkin™ and MySkinRestore™ would be appropriately assigned to the Center for Biologics Evaluation and Research (CBER) based on the combination products’ primary mode of action. (b)(4).\n\n4 We note that you had been informed by FDA prior to FDA’s inspection that MyOwnSkin™ appeared to be regulated as a combination product. Nevertheless, you continued to manufacture and distribute this product without premarketing approval until September 24, 2021.","BioLab Sciences, Inc.","biolab-sciences-inc-621465-08232022","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbiolab-sciences-inc-621465-08232022","2026-10-26T08:08:04.986053+00:00","2022-09-20","621465","Robert D. Maguire","2026-08-20T01:33:07.944+00:00","OBPO 621465","2022-08-23",8,{"510k":188,"classification":189,"enforcement":190,"event":191,"event_backfill":192,"pma":193,"warning_letter":194},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]